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Bile acids, the end-product of cholesterol catabolism, are important for absorption and 
solubilization of lipids in the intestine because of their detergent properties. In addition 
to their roles as detergents, previous studies have revealed that bile acids function as 
signaling molecules in metabolic pathways such as glucose and fatty acid metabolism as 
well as cholesterol/bile acid homeostasis. Furthermore, many reports have shown that 
bile acid signaling finely regulates numerous metabolically relevant genes at the lev^l of 
their transcription. However, the molecular mechanisms of bile acid signaling to control 
transcription of genes are poorly understood.
In recent years, two orphan nuclear receptors, famesoid X receptor (FXR) and 
small heterodimer partner (SHP), have been identified as key regulators in bile acid 
signaling. FXR was revealed as the first in vivo bile acid biosensor and was shown to 
regulate cholesterol/bile acid homeostasis by suppressing the transcription of cholesterol 
7-a hydroxylase (CYP7A1), the first and rate-limiting enzyme in bile acid biosynthesis. 
The discovery of the bile acid receptor FXR provided a better understanding 01 the 
potential roles of orphan nuclear receptors in transcriptional regulation by bile acids. 
Consecutive reports showed that bile acid-activated FXR suppressed CYP7A1 gene 
transcription by inducing another orphan nuclear receptor, small heterodimer partner 
(SHP), that plays a key role in the negative feedback regulation of bile acid synthesis. 
Later then, our group showed that bile acid-induced SHP actively recruits the 
mSin3A/HDAC corepressors and the Swi/SNF chromatin remodeling complex, 
containing Brm as a central ATPase, to the promoter and suppresses the transcription of 
the CYP7A1 gene.
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In order to delineate the repression mechanism of CYP7A1 mediated by SHP, I 
examined whether histone modifications are also involved in CYP7A1 repression by SHP 
and whether a functional interplay between chromatin modifying enzymes occurs during 
the repression of the CYP7A1 gene. Recently, I reported that histone methyltransferase 
G9a is present in a SHP complex and enhances SHP inhibitory activity to suppress 
CYP7A1 expression.
Besides cholesterol/bile acid homeostasis, FXR and SHP are involved in other 
metabolic pathways such as glucose homeostasis and fatty acid metabolism through bile 
acid signaling. Interestingly, it has been reported that the expression level of SHP was 
strikingly elevated in the liver of obese mice compared to normal mice. Also, it was 
reported that SHP-transgenic mice have significant features of fatty liver, such as lipid 
accumulation and elevated levels of hepatic triglycerides. These findings led ire to ask 
how FXR enhances the level of SHP in the liver of obese mice without bile acid signaling. 
My recent findings suggest that histone acetyltransferase p300 is a critical FXR 
coactivator for SHP induction by acetylating core histones in response to bile acid 
treatment in normal mice. However, even without bile acid treatment, p300 can 
acetylate FXR, as well as core histones, at the native SHP promoter in obese mice, 
resulting in constitutively and highly elevated expression of SHP.
These combined studies should lead to a better understanding how bile acid- 
responsive genes are regulated by the orphan nuclear receptors SHP and FXR and their 
cofactors in health and disease states.
To my Lord, Eunjung, and Luke
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C h a p te r  O n e  
Introduction
B ile  a c id s , e n d - p ro d u c ts  o f  c h o le s te ro l c a ta b o lis m , a r e  s ig n a lin g  m o lecu le s
In mammalian cells, cholesterol plays an important role in many biological activities as a
structural component of the cell membrane and as a precursor for steroid hormones, lipid 
soluble vitamins, and bile acids. Despite its essential role, excessive cholesterol causes 
toxic precipitates in blood vessels and leads to atherosclerotic heart disease and gallstone 
formation. Thus cholesterol levels in the body must be tightly regulated. The amount of 
cholesterol in the body is increased by de novo synthesis from acetyl-coA and by daily 
dietary intake, and is decreased by conversion into bile acids (73).
Cholesterol catabolism, conversion of cholesterol into bile acids, is the main 
pathway for the elimination of cholesterol from the body (16, 75, 76). Bile acids, the 
end-product of cholesterol catabolism, are important for absorption and solubilization of 
lipids in the intestine. Also, bile acids play important roles as signaling molecules in a 
wide range of metabolic pathways, such as lipid and glucose metabolism and energy 
homeostasis (18). However, the detergent properties of bile acids are toxic to the cells. 
Therefore, it is also important that the levels of cholesterol and bile acids must be 
coordinately regulated in the body. Cholesterol is converted to primary bile acids, such 
as cholic acid (CA) and chenodeoxycholic acid (CDCA), in the liver (16, 75). These 
newly synthesized primary bile acids are then secreted into the lumen of the small 
intestine where they emulsify lipids, cholesterol, and fat-soluble vitamins. In the small 
intestine, some of the primary bile acids are further converted to secondary bile acids,
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such as lithocholic acid (LCA) and deoxycholic acid (DCA) by intestinal bacteria (4, 18,
32, 82). These bile acids are efficiently absorbed from the intestine by both the ileal bile 
acid transporter (IBAT) and the ileal bile acid binding protein (IBABP) and transported 
back to the liver via enterohepatic circulation. About 95% of bile acids are recycled by 
this route; the remaining 5% are excreted from the body through the stool. The excreted 
bile acids are replaced by the bile acids newly synthesized from cholesterol in the liver.
The conversion of cholesterol to bile acids occurs by two major bile acid 
biosynthetic pathways: the alternative and classic pathways (16, 18, 75). The main bile 
acid biosynthetic pathway is the classic pathway (neutral) which produces two major 
primary bile acids, CA and CDCA, in roughly equal amounts in humans (16, 18, 22, 67, 
75). The classic pathway is initiated by cholesterol 7a-hydroxylase (CYP7A1) which is 
exclusively expressed in liver (67). The alternative pathway is initiated by sterol 27- 
hydroxylase (CYP27A1), and also named the “acidic” pathway because of the acidic 
properties of the intermediates. The alternative pathway contributes less than 18% of 
total bile acid synthesis in humans (24).
CYP7A1 is a 
member of the 
cytochrome P450 
superfamily, and a key
HO
hepatic microsomal
Chenodaoxyctotic a d d
enzyme for the 
maintenance of
Figure 1. The conversion of cholesterol into bile acids
cholesterol level
2
since it catalyzes the first and rate-limiting step in the conversion of cholesterol into bile 
acids (67). CYP7A1 incorporates a hydroxyl group at the 7a-position of the cholesterol. 
The hydroxylation at 7a initiates subsequent hydroxylation in the side chain of 
cholesterol by a number of enzymes, resulting in oxidation-dependent cleavage of side 
chains to convert cholesterol into bile acids (Fig.l).
O r p h a n  n u c le a r  re c e p to rs  a r e  in v o lv ed  in  c h o le s te ro l /b i le  a c id  h o m e o s ta s is
The bioactivity of CYP7A1 is regulated at the level of transcription by a number of 
effectors, such as insulin, steroid/thyroid hormones, cytokines, cholesterol, and bile acids, 
and also exhibits diurnal rhythm (17, 22, 58). Among these effectors, bile acids strongly 
inhibit the transcription of CYP7A1 by a negative feedback regulatory pathway. Recent 
studies have revealed that negative feedback regulation of CYP7A1 transcription by bile 
acids is mediated by the interplay of orphan nuclear receptors (16-18, 22, 73, 75, 76). 
Orphan nuclear receptors belong to the nuclear receptor superfamily and lack identified 
ligands when they were initially identified. However, recent advances in the orphan 
nuclear receptor field revealed that these receptors play critical roles in the regulation of 
glucose, lipid and drug metabolism (27, 47, 80). Nuclear receptors are DNA-binding 
transcriptional factors that are activated by lipophilic ligands, such as steroid hormones, 
vitamin D, and thyroid 
hormone. Nuclear receptors nw* bindingm, Function binding Hing«y------------  ------------N ru ti tu u
_______ A ._______ A I
consist of six domains (A-F) C--------------- ........ ....
—  COOH
based on regions of a/b c d e f Reqkn
Figure 2. The structure of nuclear receptors
conserved sequence and
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function (Fig.2). They typically have a highly conserved DNA-binding domain in the 
N-terminal region and a moderately conserved ligand-binding domain in the C-terminal 
region. Ligand-independent activation function-1 (AF-1) and ligand-dependent 
activation function-2 (AF-2) are located in the N-terminal and C-terminal regions, 
respectively. Two cysteine-Zn^ finger motifs located in the DNA-binding domain are 
directly involved in DNA binding and dimerization. The ligand-binding domain is also 
involved in dimerization and in interaction with coregulators. Upon activation by their 
ligands, nuclear receptors directly bind to specific DNA sequences in the regulatory 
regions of their target genes and usually activate gene transcription.
From promoter deletion analysis, a bile acid response element (BARE) region 
was identified in the native CYP7A1 promoter (20, 85). Numerous studies have 
reported that orphan nuclear receptors, such as hepatic nuclear factor-4 (HNF-4), liver 
receptor homolog-1 (LRH-1), small heterodimer partner (SHP), and famesoid X receptor 
(FXR), participate in the negative feedback regulation of CYP7A1 transcription by bile 
acids (14, 19, 30, 59, 68). The BARE region contains a DR-1 motif, 
TGGACT t AGTTCA (-144 to -132) that binds HNF-4 (Fig.3) (16). HNF-4 is the 
most abundant orphan nuclear receptor expressed in the liver. HNF-4 homodimers bind 
to the DR-1 motif in the
In c re a s e d  tra n s c r ip tio n
BARE region and (HNF-4)HNF-4
constitutively activate d r -1 l r h  r e
BARE (B ile A cid R e s p o n s e  E lem en t)
CYP7A l without ligand 
binding. Mutation of the
Figure 3. The structure of BARE  region
HNF-4 binding site
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substantially reduced the promoter activity of CYP7A1, indicating that HNF-4 is crucial 
for CYP7A1 gene expression (84).
In addition to HNF-4, the BARE region also contains a binding site for LRH-1 
that is required for the expression of CYP7A1 (68). LRH-1 is expressed in liver, 
intestine, and pancreas (50). The LRH-1 binding site, TCAAGGCCA (-134 to -126), 
overlaps with the HNF-4 binding site by three nucleotides in the BARE region (68). 
Whether these two orphan nuclear receptors, HNF-4 and LRH-1, bind at the same time or 
whether they compete with each other for binding at the BARE region is not well 
understood. LRH-1 is also required for the expression of SHP (56, 70). It was shown 
that SHP and transcriptional corepressors to bind to LRH-1 at the BARE region, resulting 
in repression of CYP7A1 gene expression (30, 59). Thus, LRH-1 plays an important 
role for both activation and repression of CYP7A1 transcription.
SHP is an unusual orphan nuclear receptor that contains putative ligand-binding 
and dimerization domains, but lacks a conventional DNA binding domain (Fig.4) (77). 
Studies from SHP-null mice showed that SHP is a metabolic regulator and plays a key 
role in cholesterol/bile acid and energy homeostasis (8). Previous studies showed that 
SHP interacts with numerous
1 ______ 88________153 198_________________403 4S2
nuclear receptors, such as LRH-1, RAR AF-1 DBD LBD
Zn Fingers AF-2
constitutive androstane receptor
18 27 118 129
ptsLytLLsp  p s LkkiLLeep
(CAR), HNF-4, and estrogen SHp <?—  ! p^ hv. leo f °
Ligand-binding domain
receptor (ER) and inhibits their & r*pr»s*ion domain
activities in diverse biological FjgUre 4. The comparison of domain structure of SHP 
pathways (3,41, 54, 55). with RAR' the tyPical nuc,ear recePtor
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Previous in vitro and transfection studies suggested that SHP inhibits nuclear 
receptor activity by two potential inhibitory mechanisms. First, SHP contains two 
nuclear receptor interacting LXXLL-related motifs, called NR boxes (40). Thus, SHP 
may compete with p i60 coactivators for binding to various nuclear receptors in the 
regulation of target gene transcription. Second, since SHP contains an intrinsic 
repression domain in its C-terminus, SHP may inhibit transcription by recruiting 
corepressor complexes (54). Since the orphan nuclear receptors, HNF-4 and LRH-1, are 
transcriptional activators of CYP7A1, inhibition by forming heterodimer with SHP may 
be a general mechanism for repression at the BARE region. However, whether SHP 
inhibits transcription of its target genes in a chromatin context by these proposed 
mechanisms was not demonstrated.
In addition to HNF-4, LRH-1, and SHP, FXR has been implicated in bile acid- 
mediated inhibition of CYP7A1 transcription (30, 59). The nuclear bile acid receptor, 
FXR is a biosensor for a wide variety of endogenous bile acids and primarily expressed 
in the liver, kidney, and intestine (53, 61). Previous studies have established that FXR 
indirectly inhibits CYP7A1 transcription by induction of SHP gene expression (30, 78). 
Upon activation by physiological concentration of bile acids, FXR heterodimerizes with 
retinoid X receptor (RXR) and binds to a IR-1 motif in the promoter of the SHP gene to 
activate the transcription (30, 49). Bile acid-induced SHP, then, interacts with LRH-1 at 
the CYP7A1 promoter and inhibits the transcription of CYP7A1 (30, 59). This 
inhibitory mechanism, initiated by bile acid-activated FXR, is called the SHP-dependent 
repression pathway. However, molecular mechanisms by which bile acid-induced SHP 
inhibits CYP7A1 transcription were not delineated.
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M o d if ic a t io n s  o f  c h ro m a tin  s t r u c tu r e  a re  im p o r ta n t  fo r  g e n e  e x p re s s io n
Chromatin structure plays a fundamental role in the regulation of eukaryotic gene 
function. In the chromatin of eukaryotic cells, the basic unit of organization is the 
nucleosome. One nucleosome consists of about 146 base pairs of DNA wrapped around 
a core histone octamer, w'hich contains two copies each of histones H2A, H2B, H3 and 
H4. Structural changes of chromatin play a fundamental role in eukaryotic gene 
regulation by altering the accessibility of DNA-bound factors and the basal 
transcriptional machinery to the gene (39, 83).
There are two types of chromatin-modifying complexes that are involved in 
modifying histone residues and nucleosome conformation, thereby leading to 
transcriptional activation or repression of genes. The first class contains ATP-dependent 
remodeling complexes such as, the Swi/Snf complex. These complexes modify 
chromatin structure in a non-covalent manner and the modification results in a disrupted 
or altered nucleosomal structure (91). Brm and Brg-1 are central ATPases for the 
Swi/Snf chromatin remodeling complexes. The second class includes histone 
acetyltransferases (HATs), histone deacetylases (HDACs), and histone methyltransferases 
(HMTs), which covalently modify core histones (39, 83). The core histones, 
particularly H3 and H4, can be acetylated at lysine residues in the N-terminal tails. The 
acetylation of histones mediated by HATs causes a reduction in the affinity of histones for 
DNA and results in unpacking of the nucleosome, which leads to increased access of 
transcriptional factors to DNA. The deacetylation of histones mediated by HDACs 
causes opposite effects on chromatin structure (39, 83). Transcription correlates with 
the degree of histone acetylation, with hyperacetylated regions more actively transcribed
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than hypoacetylated regions (39, 83). Likewise, histone methylation also plays an 
essential role in regulating gene transcription (48, 52, 98). In general, histone 
methylation occurs on lysine and arginine residues of histones. Methylation of K4, 36, 
and 79, and R17 and 23 of histone H3 and R3 of histone H4 have been associated with 
transcriptional activation, whereas methylation K9 and 27 of histone H3 and K20 of 
histone H4 have been correlated with gene silencing (6).
Although the detailed molecular mechanisms of CYP7A1 repression by bile 
acids are not well understood, the SHP-dependent repression pathway in response to bile 
acids is likely to converge on chromatin structural changes at the CYP7A1 promoter. 
Our lab recently found that bile acid-induced SHP was involved in in vivo chromatin 
remodeling at the human CYP7A1 promoter (45). Restriction endonuclease 
accessibility assays demonstrated that the accessibility of the core nucleosomes to 
restriction enzymes was substantially decreased after bile acid treatment, implying that 
the CYP7A1 promoter was remodeled into a more closed configuration. Biochemical 
studies indicated that SHP directly interacted with Brm and mSin3A through its 
repression domain in a mSin3A/Swi/Snf-Brm complex. Transcriptional assays in 
cultured cells showed that expression of Brm, but not a Brm ATPase mutant, inhibited 
CYP7A1 promoter activity and further enhanced SHP-mediated repression. Moreover, 
in the chromatin immunoprecipitation assays, mSin3A and the Swi/Snf-Brm complex 
were recruited to the CYP7A1 promoter in a SHP-dependent maimer. This recruitment 
was associated with chromatin remodeling after bile acid treatment. Thus, our studies 
suggested that SHP mediates recruitment of the mSin3A/Swi/Snf-Brm chromatin 
remodeling complex to the CYP7A1 promoter, resulting in chromatin remodeling and
gene repression. This study established the first link between the mSin3A/Swi/Snf-Brm 
chromatin remodeling complex and regulation of cholesterol metabolism (Fig.5) (45). 
However, the question of how the chromatin modifying enzymes, such as HDACs, HMTs, 
and the ATP-dependent chromatin-remodeling complexes, may act in concert with SHP 
to regulate CYP7A1 transcription still remain unknown.
Histone methyltransferase G9a is responsible for mono- and dimethylation of 
H3K9 in euchromatin, and is critically involved in transcriptional silencing (87, 88). 
Recently, it was reported that SHP directly interacts with G9a and potentiates SHP- 
mediated suppression in in vitro studies (9). However, the role of G9a in the regulation 
of the CYP7A1 transcription has not been studied. Thus, it prompted me to examine the 
roles of G9a in the repressive action of SHP. Recently, I found that G9a is a critical 
cofactor that is present in the inhibitory SHP complex which regulates the transcription of 
CYP7A1 in response to bile acids. This study was recently published in Molecular and 
Cellular Biology (26).
Bile acids
Figure 5. Bile Acids negative feedback CYP7A1 regulation by SHP
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T h e  n u c le a r  r e c e p to r  F X R  is a b ile  a c id  b io s e n s o r
FXR, a member of the nuclear hormone receptor superfamily, has been identified as a 
bile acid biosensor (61). FXR is mainly expressed in liver and intestine, but also at 
lower levels in the adrenal gland and kidney (53). Like many other hormone nuclear 
receptors, FXR binds to specific DNA response elements to activate the transcription of 
bile acid-responsive genes by forming a heterodimeric complex with the retinoid X 
receptor (RXR) (7, 53, 64, 66). The FXR response element (FXRE) is composed of an 
inverted repeat of 2 AGGTCA half-sites separated by 1 nucleotide (IR-1) (49). Besides 
the IR-1 motif, the FXR/RXR heterodimer can also bind to direct repeat (DR) elements 
including DR4 and DR5 in vitro (49). Physiological concentrations of endogenous bile 
acids activate FXR which then induces expression of a number of bile acid-responsive 
FXR target genes and regulates bile acid signaling pathways that control various 
metabolic processes, such as HDL, triglyceride, and glucose metabolism (51, 53, 60, 62,
92, 94), as well as cholesterol/bile acid homeostasis.
P h y s io lo g ic a l fu n c tio n a l  ro le s  o f  F X R  in  b ile  a c id  s ig n a lin g  p a th w a y
A. Role of FXR in triglyceride and lipoprotein metabolism In the early 1970s,
patients with gallstones were orally treated with chenodeoxycholic acid (CDCA) which 
enhanced the concentration of bile acids and thus solubilized the cholesterol-rich stones. 
Interestingly, this treatment reduced the plasma triglyceride levels both in the patients 
suffering from gallstones and in those with hypertriglyceridemia (5, 65). Studies in 
FXR-null mice indicated that bile acids and FXR play important roles in triglyceride 
metabolism. The levels of HDL-cholesterol are elevated in FXR-null mice, which
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results in hypercholesterolemia (78). Notably, administration of FXR agonists to 
normal rats and mice reduced plasma triglyceride levels (44, 63).
Recently, FXR has been suggested to promote the hepatic clearance of 
lipoproteins and reduce plasma cholesterol levels. It was shown that bile acid-activated 
FXR induces its target gene SHP which correlates with decreased expression of the 
master lipogenic regulator sterol regulatory element binding protein (SREBP)-lc, 
providing a potential mechanism for the triglyceride-lowering effect of bile acids (92). 
FXR activation with natural and synthetic agonists induces ApoCII which activates LPL, 
a key enzyme involved in lipoprotein lipolysis, and suppresses ApoCIII, an inhibitor of 
LPL activity (21, 44, 53). Consistent with this finding, FXR induces the expression of 
the phospholipid transfer protein (PLTP), an enzyme which transfers phospholipid groups 
from triglyceride-rich lipoproteins to HDL (90). Moreover, activated FXR induces the 
expression of the very-low-density lipoprotein receptor (VLDL Rc) which plays a key 
role in the metabolism of lipoproteins by enhancing LPL-mediated triglyceride hydrolysis 
(79). Thus, FXR controls important genes involved in triglyceride and lipoprotein 
metabolism.
B. Role of FXR in glucose metabolism Recently, in in vitro and in vivo studies it was 
shown that bile acids modulate gluconeogenesis by regulating the expression of the rate- 
limiting enzyme, phosphoenolpyruvate carboxykinase (PEPCK), as well as glucose-6- 
phosphatase (G6Pase). The expression of PEPCK and G6Pase genes are negatively 
regulated by bile acid treatment in vivo (94). This study showed that the negative 
regulation of PEPCK and G6Pase resulted from the induction of SHP (94). hi addition,
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it has been shown in FXR-null mice that circulating free fatty acids were increased, 
which was associated with elevated plasma glucose and impaired glucose and insulin 
tolerance (11). Activation of FXR in wild type or diabetic mice promoted 
hypoglycemia and increased insulin sensitivity (11, 97).
C. Other physiological functions of FXR in response to bile acids FXR also plays a 
critical role in protecting the liver from toxic bile acids (53). Like CYP7A1 inhibition, 
the FXR/SHP pathway is also involved in repression of Na"-taurocholate contransporting 
polypeptide (NTCP), a hepatic bile acid import transporter that mediates the entry of 
intestinal bile acids into hepatocytes (23). When hepatic bile acid levels are elevated, 
FXR induces SHP and thereby represses CYP7A1 and NTCP, resulting in inhibition of 
both bile acid biosynthesis and uptake of intestinal bile acids, respectively. Thus, the 
FXR/SHP pathway can prevent excess accumulation of bile acids in the liver. Besides 
NTCP, bile acid-activated FXR also protects the liver from elevated toxic bile acids by 
increasing the export of hepatic bile acids to the gall bladder. Bile salt export pump 
(BSEP) is a major bile acid transporter that mediates the transport of bile acids across the 
canalicular membrane into the bile duct and its expression is induced by FXR. Bile 
acid-activated FXR induces the expression of BSEP and reduce accumulation of hepatic 
bile acids to protect the liver from elevated hepatic bile acids (1). Therefore, FXR plays 
a critical role in protecting the liver from elevated hepatic bile acids via inhibition of bile 
acid synthesis and bile acid import from the intestine, and induction of excess bile acid 
export from the liver to the gall bladder.
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FXR is also important in the liver regeneration process (37). Treatment of mice 
with cholic acid resulted in accelerated liver regeneration, and this effect was markedly 
reduced in FXR-null mice (37). Therefore, it has been proposed that FXR regulates the 
size or regeneration of the liver in response to the levels of bile acids. In addition, FXR 
protects the intestine from the bacterial growth. CYP27-null mice have impaired bile 
acid synthesis which results in decreased FXR activation and FXR target gene induction 
(38). Treatment of CYP27-null mice with a FXR agonist, GW4064, repressed mucosal 
injury in the intestine due to attenuated intestinal bacterial overgrowth, whereas FXR-null 
mice did not have any beneficial effect (38). Thus, it has been suggested that FXR- 
mediated transactivation provides protection from bacterial overgrowth. Although such 
important physiological roles of FXR have been revealed, the molecular mechanisms by 
which FXR mediates such diverse metabolic pathways in response to bile acids are not 
known.
M o d u la t io n  o f  F X R  ac tiv ity 7 b y  t r a n s c r ip t io n a l  c o fa c to rs
Nuclear receptors collaborate with a number of transcriptional cofactors, such as 
coactivators and corepressors, to regulate expression of their target genes. Ligand 
binding induces conformational changes in nuclear receptors and promotes their 
association with a diverse group of nuclear proteins, such as SRC-1/p i60, SRC-2/TIF- 
2/GRIP-l, SRC-3/AIB1 and CBP/p300 which function as coactivators of transcription 
(12, 28, 33, 71, 86). In the absence of ligand, several nuclear receptors, such as TR, 
LXR, and PXR, associate with corepressors, such as HDAC, SMRT, and NcoR-1, and 
maintain target genes in a repressed state (15, 34, 35, 42, 89, 93). Previous in vitro and
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functional reporter studies suggested that several transcriptional cofactors may 
collaborate with 1XR to modulate its target genes. The histone arginine 
methyltransferase, CARM1, methylates histones at the promoter of the BSEP gene and 
increase the activity of FXR (2). Another arginine methyltransferase, PRMT1, 
methylates histones at the SHP and BSEP promoters and enhances transactivation by 
FXR (74). A transcriptional cofactor and mediator, DRIP205, was also shown to 
interact with FXR in vitro and enhanced transcriptional activation by FXR in reporter 
assays (72). A metabolic coactivator PGC-la and GRIP-1, a p i60 coactivator, have 
been shown to directly interact with FXR in vitro and increase FXR transactivation in 
reporter assays (43, 96). However, whether these cofactors modulate FXR 
transactivation in response to bile acids in vivo has not been delineated.
p300 is a transcriptional coactivator that is involved in the regulation of various 
DNA-binding transcriptional factors (29). p300 was initially identified in protein 
interaction assays by its interaction with the adenoviral-transforming protein El A (25) 
and identified as a histone acetyltransferase (69). The correlation between histone 
acetylation and gene activation has been documented (6, 39), therefore, the finding that 
p300 was a histone acetyltransferase indicated that p300 functions as a transcriptional 
coactivator by modulating the covalent modifications of chromatin. Acetylation by 
p300 was shown to regulate the transcriptional functions of non-histone proteins as well 
(31). Several transcriptional regulators were shown to be acetylated, including ER, 
HNF-4, EKLF, GATA-1, p53, NF-Y, and ACTR (10, 13, 31, 46, 57, 81, 95). 
Acetylation of these proteins by p300 affects their transcriptional activity by altering 
DNA binding, cofactor interaction, stability, and subcellular localization.
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Although the essential biological roles of FXR have been determined, how FXR 
modulates the transcription of the target genes is poorly understood. Therefore, to 
broaden my interests and understanding of bile acid signaling pathway in the liver, I have 
been investigating whether p300 can modulate FXR activity for regulation of the 
transcription of the target genes, including SHP, a well known FXR target gene in bile 
acid signaling. Previous study showed that SHP-transgenic mice have a fatty liver- 
phenotype (8). Consistent with these data, a recent study showed that SHP expression 
was abnormally elevated in obese mice, suggesting that dysregulation of SHP expression 
may lead to hepatic metabolic disease (36). Thus, I also have investigated the role of 
FXR and p300 in dysregulated SHP expression in obese mice.
Recently, I found that p300 plays a critical role in FXR transactivation in the 
induction of the expression of SHP through bile acid signaling. Moreover, p300 can 
constitutively acetylate FXR, as well as core histones, in obese mice in the absence of 
bile acid signaling, resulting in dysregulated hepatic SHP expression in the liver.
SHP and FXR play key roles in glucose and triglyceride metabolism, as well as 
in cholesterol/bile acid homeostasis. The physiological roles of SHP and FXR have 
been exclusively studied, however, the molecular mechanisms and the pathways by 
which they regulate the expression of target genes involved in hepatic metabolism have 
not been explored in detail. Thus, my study will provide information about the 
regulation of the expression of these genes that may help in developing novel therapeutic 
agents to treat metabolic disorders, such as, hyperlipidemia and atherosclerosis.
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C h a p te r  T w o
Roles of the key metabolic regulator SHP and its cofactor, 
histone methyltransferase G9a in the regulation of bile acid biosynthesis 
Abstract
SHF has been implicated as a pleiotropic regulator of diverse biological functions by its 
ability to inhibit numerous nuclear receptors. Recently, we reported that SHP inhibits 
transcription of CYP7A1, a key gene in bile acid biosynthesis, by recruiting HDACs and 
a Swi/Snf-Brm complex. To further delineate the mechanism of this inhibition, we have 
examined whether methylation of histones is also involved and whether a functional 
interplay between chromatin modifying enzymes occurs. Histone methyltransferase, 
G9a was colocalized with SHP and directly interacted with SHP in vitro. G9a, that was 
coimmunopreciptated with hepatic SHP, methylated lys-9 of histone 3 (H3K9) in vitro. 
Expression of G9a enhanced inhibition of CYP7A1 transcription by SHP, while a 
catalytically inactive G9a dominant negative (DN) mutant reversed the SHP inhibition. 
G9a was recruited to and H3K9 was methylated at the CYP7A1 promoter in a SHP- 
dependent manner in bile acid-treated HepG2 cells. Expression of the G9a-DN mutant 
inhibited H3K9 methylation, blocked the recruitment of the Brm complex, and partially 
reversed the CYP7A1 inhibition by bile acids. Inhibition of HDAC activity with 
trichostatin A (TSA) blocked deacetylation and methylation of H3K9 at the promoter, 
and conversely, inhibition of H3K9 methylation by G9a-DN partially blocked 
deacetylation. Hepatic expression of G9a-DN in mice fed cholic acid disrupted bile acid 
homeostasis, resulting in increased bile acid pools and partial de-repression of Cyp7al
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and Cyp8bl. Our studies establish a role for G9a methyltransferase, histone 
deacetylases, and the Swi/Snf-Brm complex in the SHP-mediated inhibition of bile acid 
synthesis via coordinated chromatin modification at target genes.
Introduction
The small heterodimer partner (SHP, NR0B2), an unusual orphan nuclear receptor which 
lacks a DNA binding domain but contains a putative ligand binding domain, interacts 
with a number of nuclear receptors including LRH-1, HNF-4, ERR, CAR, LXR, GR, and 
ER, and inhibits their transcriptional activities (1, 4, 7, 30, 39, 40). Thus, SHP acts as a 
pleiotropic transcriptional repressor affecting diverse biological functions, including 
cholesterol and glucose metabolic pathways, energy homeostasis, and reproductive 
biology (2). SHP has been shown to be a key regulator in the negative feedback 
regulation of bile acid biosynthesis from cholesterol in the liver (15, 25, 31, 48). Bile 
acid-activated FXR, upon heterodimerization with RXR, binds to the promoter of the 
SHP gene and increases transcription (15, 31). The bile acid-induced SHP then 
suppresses transcription of CYP7A1 and CYP8B1, key hepatic genes involved in the 
neutral pathway of bile acid biosynthesis, by interacting with LRH-1 and/or HNF-4, 
which are bound to the promoters of the genes. In addition to regulation of bile acid 
biosynthesis by SHP, recent studies show that bile acid-induced SHP also inhibits 
expression of hepatic bile acid transporters, such as, NTCP and BSEP (5, 11, 13). Bile 
acid homeostasis was disrupted in SHP-null mice, establishing an in vivo physiological 
role of SHP in the regulation of cholesterol/bile acid metabolism (25, 48).
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Previous studies showed that SHP interacts with the AF-2 domain of nuclear 
receptors through the LXXLL motifs in SHP and subsequently inhibits the activity of 
nuclear receptors by competing with coactivators (20, 21, 29). In addition to this 
coactivator competition model, it was also proposed that SHP could directly repress the 
activities of nuclear receptors via its C-terminal intrinsic repression domain, presumably 
by recruiting corepressors (29, 30). However, the molecular mechanisms underlying 
the direct suppression of transcription by SHP have not been well defined and the 
mechanisms of SHP action at target genes in a natural chromatin context are largely 
unexplored. Recently, we reported that SHP mediates repression by recruiting 
chromatin modifying enzymes including the mSin3A/HDACl/2 corepressor and 
Swi/Snf-Brm chromatin remodeling complexes to the CYP7A1 promoter in HepG2 cells 
after bile acid treatment, which results in histone deacetylation and chromatin remodeling 
(24).
Chromatin structure plays a fundamental role in the regulation of eukaryotic gene 
activity (23, 26, 50). Primary structural units of chromatin are nucleosomes, which 
suppress transcription by imposing a barrier for access of transcription factors and basal 
transcriptional machinery to DNA. ATP-dependent chromatin remodeling complexes, 
such as Swi/Snf, weaken DNA/histone contacts in the core nucleosome, which may 
disrupt or alter nucleosomal conformation (23, 50). The Swi/Snf complexes contain 
either of two ATPases, Brm or Brg-1, and variable subunits of Brm or Brg-1 associated 
factors (BAFs). Brm and Brg-1 preferentially interact with different types of 
transcription factors and target promoters (22). Recent studies, including ours, show 
that these Swi/Snf complexes are involved in gene repression as well as activation (24,
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51). A second class of chromatin modifying complexes includes enzymes that are 
involved in covalent modification of core histone tails, such as, acetylation and 
methylation of lysine (19, 44). While histone acetylation generally correlates with 
transcriptional activation (19), histone methylation has either negative or positive effects 
on transcription, depending on the residue methylated and the type of modification (19,
27, 38). Methylation at lys-9 of histone 3 (H3K9) has been correlated with 
transcriptional silencing in most cases, whereas methylation at lys-4 of histone 3 (H3K4) 
is associated with gene activation. The mammalian histone methyltransferase, G9a, is 
responsible for mono- and di-methylation of H3K9 in euchromatin (45). Studies in 
G9a-null mice showed that euchromatic H3K9 methylation by G9a is essential in early 
embryogenesis and is critically involved in transcriptional silencing of developmentally 
regulated genes (46). In contrast, SUV39H1, a heterochromatic histone lysine 
methyltransferase, directs trimethylation of H3K9 in pericentric heterochromatin and this 
modification creates a binding motif for the HP1 protein that is directly associated with 
DNA methylation and gene silencing (27, 43).
Our previous study showed that SHP interacts with HDAC-1, HDAC-2, and 
mSin3A corepressors and recruits these factors to the CYP7A1 promoter in response to 
bile acid treatment (24). We further observed that acetylation of histones H3 and H4 in 
the CYP7A1 promoter was markedly decreased in a SHP-dependent manner after bile 
acid treatment. Consistent with our observations are recent reports that SHP interacts 
with HDACs and that its repressive effects are mediated through recruitment of HDACs 
(14). It was also shown from a recent interesting study that SHP functionally interacts 
with HDAC-1 and with G9a in cells (6), but a role for G9a in SHP-mediated suppression
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of genes involved in hepatic bile acid metabolism has not been demonstrated. Since 
CY P7A1 and CYP8B1, two key genes in hepatic bile acid biosynthesis, are well-known 
SHP target genes, we explored whether H3K9 methylation catalyzed by G9a at the 
promoters of the endogenous CYP7A1 and CYP8B1 genes is critical for SHP-mediated 
feedback inhibition of the expression of these genes by bile acids. Since HDACs and 
Brm have been shown to be involved in gene repression by SHP (24), another important 
question is whether coordinated enzymatic modification of histones by G9a and HDACs 
and ATP-dependent remodeling by the Swi/Snf-Brm complex at the CYP7A1 promoter 
are critical for transcriptional silencing mediated by bile acid-induced SHP. We found 
that H3K9 methylation by G9a and H3K9 deacetylation by HDACs are interdependent 
and necessary for the recruitment of the Swi/Snf-Brm complex, which is essential for 
SHP-mediated transcriptional silencing of the CYP7A1 gene. Interestingly, inhibition 
of hepatic G9a activity in mice by expression of a dominant negative mutant of G9a 
partially de-repressed Cyp7al and CypSbl, and resulted in elevated bile acid pools in 
mice fed cholic acid. Our studies establish a critical role for these chromatin modifying 
enzymes in the suppression of SHP target genes involved in hepatic bile acid metabolism.
Materials and Methods 
C e ll c u l tu r e  a n d  H e p G 2  s ta b le  ce lls
Human hepatoma HepG2 cells (ATCC HB8065) were grown in phenol red-free 
Dulbecco’s modified Eagle’s medium/F12 (1:1). Cos-1 and human embryonic cells- 
derived Ad-293 cells (Cell Biolabs, Inc) were maintained in DMEM media. Media 
were supplemented with 100 units/ml penicillin G-streptomycin sulfate and 10% heat
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inactivated fetal bovine serum. For ChIP and RTPCR experiments, HepG2 cells were 
seeded, and incubated and treated with 25-50 CDCA (Sigma) for 6 hr to 18 hr in 
serum-free media. Because we observed that the response of the HepG2 cells to bile 
acids was often diminished after long-term culture, new cultures were established every 
6-8 weeks from frozen aliquots of our original HepG2 cell culture. In addition, the 
effect of CDCA on CYP7A1 and SHP mRNA levels was regularly assessed to ensure that 
the response of the cells to CDCA had not been changed. To construct a HepG2 cell 
line with the CYP7Al-luc reporter stably incorporated into the genome, a DNA fragment 
containing human -1887 CYP7Al-luc (8), was inserted into pcDNA3 in which the CMV 
promoter had been removed. HepG2 cells were transfected with the pcDNA3-CYP7Al- 
luc plasmid and selected with 800|ig/ml of G418 for 2-3 weeks. Drug-resistant colonies 
were pooled and expanded, and subjected to luciferase assays to ensure that the CYP7A1- 
luc plasmid was stably incorporated into genome.
T ra n s f e c t io n  r e p o r t e r  a ssa y s
For transient transfections, HepG2 or Cos-1 cells were cotransfected with DNA of the - 
1887 human CYP7Al-luc reporter (8), Gal4-TATA-luc reporter (29), G4DBD, G4DBD- 
HNF-4 (130-368) (28), pcDNA3-PGC-la (3), pcDNA3-SHP (24), pCMV-HNF-4, 
pcDNA3.1-G9a (16), pEGFP-G9a (36), pcDNA3.1 G9a-DN (16), or pcDNA3.1-HA- 
SUV39H1 (34) as indicated in the figure legends. Empty vector DNA was added as 
needed so that the same amounts of CMV expression vector DNA were present in each 
transfection. Transfection was carried out using lipofectamine 2000 in 24-well plates. 
Twenty-four hr after transfection, cells were collected and luciferase and 6-galactosidase
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activities were determined. Firefly luciferase activities were divided by fi-galactosidase 
activities to normalize lor transfection efficiency. Consistent results were observed in 
2-4 independent triplicate transfection assays in each experiment.
C o n s tr u c t io n  o f  p la s m id s  a n d  a d e n o v ira l  v e c to rs
Plasmid pGEX411-SHP region 1 (amino acids 1-92) was constructed by PCR 
amplification of mouse SHP using forward and reverse primers which contained BamHl 
and Xhol sites, respectively. The PCR product was digested with BamHl and Xhol 
and inserted into pGEX4T-l digested with the same enzymes. Recombinant 
adenoviruses, Ad-si human SHP and Ad-G9a-DN, wrere constructed with the Ad-Easy 
system (18) in which the recombinant adenoviruses also express GFP. For the 
construction of Ad-G9a-DN virus, a Hind HI/EcoRV fragment encoding G9a-DN from 
pcDNA3.1G9a-DN (16) was inserted into Ad-Track CMV shuttle vector. For the 
construction of Ad-human SHP siRNA, the pSUPER vector containing the siRNA for 
human SHP (+76 to +94) (24) was digested with EcoRl and filled-in with the Klenow 
fragment of E.coli DNA polymerase, and further digested with Hind III, and cloned 
between the EcoRV and Hind III sites of the Ad-Track vector (18). E. coli BJ5183 
cells, that contain the AdEasy backbone vector, were transformed with the Ad-Track 
vector DNA that was linearized by Pmel digestion. Homologous recombination via 
adenoviral sequences in the shuttle vector and backbone vector in these cells yielded the 
recombinant adenoviral vectors. The recombinant viral vectors were characterized by 
P ad  digestion to ensure that no rearrangement had occurred. Ad-293 cells were 
transfected with the recombinant adenoviral DNA, and the recombinant virus was then
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amplified by several rounds of infection of the Ad-293 cells. The viruses were isolated 
by CsCl2 step gradient centrifugation as described (18) and dialyzed in PBS/10% 
Glycerol. Total viral particles were determined by absorbance at A260 (1 A260 unit is 
approximately 1 x 101" particles) and the number of active viral particles were 
determined by measurement of cells expressing GFP by confocal microscopy.
In vivo e x p e r im e n ts
BALB/c male mice (8-12 weeks old) were maintained on a 12 hr light and 12 hr dark 
cycle. For ChIP assays, mice were randomly divided into groups that w'ere fed normal 
chow or normal chow supplemented with 0.5% cholic acid for indicated times (5 hr to 24 
hr). For in vivo G9a-DN experiments, mice were injected with about 1 x 109 active viral 
particles in 500jil PBS via the tail vein, and 3 days after infection, the mice were briefly 
fasted for 5 hr to synchronize feeding and then fed normal or the 0.5% cholic acid- 
containing chow for 5 hr or 24 hr. Feeding with cholic acid-containing diets was always 
started at 5:00 P.M. The liver, gall bladder, and entire small intestine were collected for 
further analyses.
M e a s u r e m e n t  o f  to ta l  b ile  a c id  p o o l s ize
Bile acid pools were colorimetrically measured using a diagnostic bile acid analysis kit 
(Trinity Biotech) as described (48). Briefly, gall bladder, parts of liver directly 
surrounding the gall bladder, and the entire small intestine were collected for measuring 
the total pool of bile acids. Samples were homogenized, and bile acids were extracted
35
in 75% ethanol at 50°C for 2 hr, followed by centrifugation. The bile acid pool size was 
calculated as (unoles of bile acid per gram of body weight.
R e a l t im e  R T P C R
1 otal RNA was isolated from mouse liver or HepG2 cells using Trizol reagent and cDNA 
was synthesized using a reverse transcriptase kit (Promega Inc.). Real-time RTPCR was 
performed with an iCycler iQ (Biorad, Inc) following the manufacturer’s instructions. 
The amount of PCR product for each mRNA was normalized by dividing by the amount 
of G-actin or 36B4 PCR product. Each real time RTPCR was repeated at least three 
times with similar reproducible results.
C o lo c a liz a t io n  s tu d y
Cos-1 cells were seeded on cover slips in 6-well plates and cotransfected with expression 
plasmid DNA for GFP-SHP, G9a, or SUV39H1. Twenty-four hr after transfection, cells 
were fixed with 2.5% paraformaldehyde and permeabilized with 0.1% Triton X-100. 
Samples were blocked with 3% BSA for 30 min, incubated with rabbit G9a antibody 
(1:50) or HA rat monoclonal antibody (Roche Inc., 1:25) for 30 min, washed, and then 
incubated with Rhodamine-conjugated secondary antibody (1:200) for 30 min. 
Mounting medium was added and green fluorescence and red immunfluorescence were 
detected with a Zeiss LSM confocal microscope as before (3, 33).
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C o im m u n o p re c ip i ta t io n  (C o IP )  a ssa y
CoIP assays were performed as described with minor modifications (3, 24). Cell extracts 
or nuclear extracts from HepG2 cells or mouse liver were incubated in lysis buffer (20 
mM KOH-Hepes, pH 8.0, 0.2 mM EDTA, 5% glycerol, 250 mM NaCl, 0.5% NP40, 
0.25% sodium deoxycholate, 1 mM DTT, and protease inhibitors) with antibodies against 
G9a or SHP or rabbit IgG at 4° C for 4 hr to overnight and the immune complex was 
collected by incubation with 30 (il of a 25% slurry of protein A or G agarose for 2 hr. 
Immunoprecipitates were washed four times with lysis buffer supplemented with NaCl to 
400 mM and subjected to western blotting or used in in vitro HMT assays.
G S T  p u ll  d o w n  a ssa y
GST-SHP fusion proteins (7) and GST-G9a (621-1000) (45) wrere expressed in E. coli 
BL21/DE3/RIL (Stratagene, Inc.) and purified by binding to glutathione-Sepharose 
(Pharmacia, Inc.). 3'S-labeled SHP or G9a was synthesized by the in vitro TNT system 
(Promega, Inc.). GST pull down assays were performed as described (3, 24). Briefly, 
one jig of the GST fusion proteins was incubated with 35S-labeled proteins in incubation 
buffer (20 mM KOH-Hepes, pH 7.8, 0.1 mM EDTA, 10% glycerol, 100 mM KC1, 0.5% 
NP40, protease inhibitors, 1 mM DTT) at 4°C for 2 hr. After washing 5 times with 
incubation buffer, proteins associated with GST fusion proteins were analyzed by SDS- 
PAGE. Five ng of GST-SHP or GST was incubated with 0.5 mg or 1.4 mg protein of 
HepG2 and mouse liver nuclear extracts, respectively, in incubation buffer at 4°C for 2 
hr. After washing 4 times with incubation buffer (supplemented to 400 mM NaCl and
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0.5/o M 40), proteins associated with GST-SHP or GST were subjected to western 
blotting or HMT assays.
H is to n e  m e th y l ta n s fe r a s e  (H M T ) assay s
HMT assays were performed as described with minor modifications (12, 16, 36, 43). 
Briefly, anti-SHP immunoprecipitates or GST-SHP protein complexes were washed with 
IX HMI buffer (50 mM Tris-HCl, pH 8.0) twice and incubated with 2 |ig of core 
histones isolated from HeLa cells or 2 jig of bacterially expressed and purified GST-H3 
(1-84) or GST-H3R9 as histone substrates in HMT buffer containing 0.25 jiCi of S- 
adenosyl methyl Tl-methionine at 30°C for 1 hr with occasional gentle mixing. Proteins 
were separated by SDS-PAGE and visualized by Coomassie blue staining and 
radioactivity was detected by autoradiography.
C h r o m a t in  im m u n o p re c ip i ta t io n  (C h IP )  assay s  in  m o u se  l iv e r  a n d  H e p G 2  cells
ChIP assays in HepG2 cells and in mouse liver were carried out essentially as described 
(3, 24, 32). Briefly, livers were finely minced and incubated in PBS containing 1% 
formaldehyde at room temperature for 10 min, and glycine was added to stop the 
reaction. Cells were resuspended in hypotonic buffer (10 mM KOH-Hepes, pH 7.9, 1.5 
mM MgCl2, 10 mM KC1, 0.2% NP40, 0.15 mM spermine, 0.5 mM spermidine, 1 mM 
EDTA, 5% sucrose) and lysed by homogenization. Nuclei were pelleted and 
resuspended in sonication buffer (50 mM Tris-HCl, pH 8.0, 2 mM EDTA, 0.85% SDS). 
The samples were sonicated to reduce DNA length to between 200-1,000 bp. After 
centrifugation, the chromatin sample was pre-cleared and further immunoprecipitated
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with 1-3 jig of antisera at 4 C for overnight. G9a antibody was kindly provided by Y. 
Nakatani (37, 41) and SHP antibody was described previously (7, 21). Antibodies 
against acetylated histone H3, diacetylated H3K9/K14, dimethylated H3K9, and HDAC- 
1 were purchased from Upstate Biotech and antibodies against Brm, BAF170, mSin3A, 
HDAC-2, HDAC-3, and NcoRl, were purchased from Santa Cruz Biotech. The 
immune complex was collected and the beads were extensively washed and the bound 
chromatin was eluted as described (3, 24, 32). Genomic DNA was purified by organic 
extraction and used as a template for semi-quantitative PCR. The linearity of the PCR 
reactions was established using different number of cycles and different amounts of 
template.
For cells infected with adenoviral vectors before ChIP assays in HepG2 cells, 
confluent cells in 15 cm plates (2 x 10 ) were infected at a MOI of 10 with adenoviruses, 
and 24 hr after infection, cells were treated with CDCA or vehicle for indicated times 
before collection of cells for ChIP assays. For TSA experiments, HepG2 cells were 
pretreated with 100 nM of TSA for 1 hr before 25 jiM of CDCA treatment for 7 hr and 
cells were then collected for either real time RTPCR or ChIP assay.
Results
G 9 a  is a s s o c ia te d  w ith  S H P  in  m o u se  liv e r a n d  H e p G 2  ce lls
SHP recruited HDAC-containing corepressor complexes to the native CYP7A1 promoter, 
which resulted in histone deacetylation and transcriptional repression after bile acid 
treatment (24). Since histone methylation as well as deacetylation are functionally 
correlated with gene repression (19, 27, 44), we examined if G9a and SUV39H1,
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euchromatic and heterochromatic histone lysine methyltransferases, respectively (27), 
colocalize with SHP in the nucleus. Cos-1 cells were cotransfected with expression 
plasmid DNA for either G9a or SUV39H1 and GFP-SHP. SHP was detected by GFP 
fluorescence and G9a or SUV39H1 was detected by immunofluorescence in cells imaged 
by confocal microscopy. Staining of G9a (Fig. 1A) and SUV39H1 (Fig. IB) was 
localized diffusely in the nucleus with patches of higher intensity. SHP was present in 
both the cytoplasm and nucleus with bright punctuated fluorescence as well as more 
diffuse patches of increased fluorescence. In 80% of the cells observed, the positions of 
the brighter patches of fluorescence of GFP-SHP overlapped patches of increased 
staining of G9a, but not that of SUV39H1, consistent with colocalization of SHP and G9a 
in the nucleus.
Next, we examined if G9a associates with SHP in mouse hepatocytes in vivo 
and human hepatoma HepG2 cells. Nuclear extracts from mouse liver and HepG2 cells 
were incubated with either GST-SHP or GST bound to glutathione-Sepharose. After 
washing the beads, the bound proteins were analyzed by western blotting. G9a was 
pulled-down from both extracts by GST-SHP, but not by GST (Fig. 1C). In addition, 
interaction between endogenous SHP and G9a in HepG2 cells was examined by co- 
immunoprecipitation. HepG2 nuclear extracts were immunoprecipitated with antisera 
against SHP, G9a, or control IgG, and the immunoprecipitates were analyzed by western 
blotting. G9a was detected in the anti-SHP immunoprecipitates and conversely, SHP 
was detected in the anti-G9a immunopreciptiates (Fig. ID). These results indicate that 
endogenous SHP interacts directly, or indirectly within a complex, with endogenous G9a 
in hepatic cells.
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To test if G9a can directly interact with SHP, GST fusions with SHP or 
fragments of SHP (Hg.IE) that had been bound to glutathione-Sepharose were incubated 
with S-labeled G9a. G9a bound to SHP or SHP mutants containing the N-terminal 
domain (1-92 amino acids), whereas no binding was detected with SHP mutants lacking 
this region (Fig. 1F). In parallel experiments (not shown), the C-terminal domain (amino 
acids 160-260) of SHP was required for its interaction with mSin3A and Brm as 
previously reported (24). To examine if the C-terminal catalytic SET (Su (var\ 
Enhancer of Zeste, Trithorax) domain of G9a was sufficient for interaction with SHP, a 
GST-G9a C-terminal fragment containing amino acids 621-1000 (Fig.lG) was bound to 
the glutathionine-Sepharose and incubated with °S-labeled SHP. The GST-G9a C- 
terminal fragment efficiently interacted with SHP (Fig. 1H). These results indicate that 
the N-terminus of SHP is required for direct interaction with G9a and that the C-terminal 
SET domain of G9a is sufficient for direct interaction with SHP in vitro.
G 9 a  c o im m u n o p re c i ta te d  w ith  S H P  m e th y la te s  H 3 K 9  in vitro
If the G9a associated with SHP is functionally active, then, histone methyltransferase 
activity (HMT) should be detected in the protein complex immunoprecipitated by SHP 
antisera. SHP-containing protein complexes from mouse liver or HepG2 nuclear 
extracts were obtained by immunoprecipitation with SHP antibody or by binding to GST- 
SHP and used in in vitro HMT assays. Histone H3 was methylated in reactions 
containing proteins pulled down by GST-SHP from nuclear extracts of mouse liver or 
HepG2 cells while proteins pulled down by GST did not exhibit HMT activity (Fig. 2A). 
Further, western blotting with antibody specific for dimethyl H3K9 revealed that the
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methylation of histone H3 in the HMT reaction included methylation at K9 (Fig. 2B). 
Histone 113 was also methylated in reactions containing anti-SHP immunopreciptiates 
from HepG2 nuclear extracts, but not in reactions containing immunoprecipitates with 
control IgG (Fig. 2C). Since G9a is pulled down by GST-SHP (Fig. 1) and specifically 
catalyzes K9 methylation of histone H3 (45), these results are consistent with the 
conclusion that the H3K9 methylation was catalyzed by G9a. To directly determine 
whether the G9a in the SHP complex catalyzes H3K9 methylation, wre utilized a 
catalytically inactive G9a dominant negative mutant (G9a-DN) in HepG2 cells. The 
G9a-DN contains two amino acid substitutions within the catalytic SET domain and 
efficiently blocked activity of wild type G9a in the PRD-BF1 -mediated inhibition of the 
interferon 6 gene (16). The G9a-DN interacted as efficiently as wild type with the N- 
terminus of GST-SHP in GST pull down assays (not shown). HepG2 cells were 
infected with adenoviral vector encoding G9a-DN (Ad-G9a-DN) or control empty vector 
(Ad-empty) and the cells were further subjected to real-time RTPCR, western blotting, or 
coimmunoprecipitation followed by in vitro HMT assays (Fig. 2D). The adenoviral 
vectors express green fluorescence protein (GFP) and GFP fluorescence was detected in 
over 90% of cells by confocal microscopy (not shown).
RTPCR and western blotting revealed that mRNA and protein levels of total 
G9a (endogenous G9a and G9a-DN) were substantially increased in HepG2 cells infected 
with Ad-G9a-DN (Fig. 2E). HMT activity in anti-SHP or control IgG 
immunoprecipitates of extracts from the HepG2 cells infected with Ad-empty or Ad-G9a- 
DN was analyzed using purified GST-H3 (1-84) as the substrate. Methylation of GST- 
113 was observed with the anti-SHP immunoprecipitates of extracts from cells infected
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with Ad-empty. However, methylation of GST-H3 was not observed in the anti-SHP 
immunoprecipitates from cells infected with Ad-G9a-DN (Fig. 2F), which indicates that 
G9a is responsible for the observed methylation of GST-H3. To provide further 
evidence that the residue methylated was Lys-9, purified GST-H3R9, in which Lys-9 is 
mutated to Arg, was added as substrate in the reactions. GST-H3R9 was not methylated 
in reactions containing anti-SHP immunoprecipitates from cells infected with either Ad- 
empty or Ad-G9a-DN (Fig. 2F). Control IgG immunoprecipitates did not show any 
HMT activity (Fig. 2F). These results provide evidence that G9a is present in a hepatic 
SHP complex and is catalytically active for methylation of H3K9.
G 9 a  in c r e a s e s  in h ib i t io n  o f  C Y P 7 A 1  t r a n s c r i p t io n  b y  S H P
HNF-4 and its coactivator PGC-la transactivate the CYP7A1 promoter and are well- 
known targets of SHP inhibition (4, 10, 24, 29, 42). Therefore, we determined whether 
exogenously expressed G9a increases the inhibition of HNF-4/ PGC-la activation by 
SHP using a Gal4 reporter system in transfected Cos-1 cells. Expression of PGC-la 
dramatically increased HNF-4 transactivation and increasing amounts of SHP 
progressively suppressed the HNF-4/PGC-la activation (Fig. 3A, lanes 4-7). 
Transfection of increasing amounts G9a expression plasmid with a constant amount of 
SHP plasmid increased inhibition of the HNF-4/ PGC-la activation in a dose-dependent 
manner (Fig. 3A, lanes 8-11, Fig. 3B, lanes 3,4). In contrast, expression of the 
heterochromatic histone methyltransferase, SUV39H1, did not enhance SHP-mediated 
inhibition, but slightly increased transcription (Fig. 3B, lanes 5, 6). These results are
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consistent with our observations that G9a, but not SUV39H1, colocalized with SHP in 
Cos-1 cells and that G9a is present in SHP-containing complexes (Fig. 1).
To test if G9a inhibition of HNF-4/PGC-la activation is dependent on SHP, G9a 
was expressed in transfected Cos-1 cells with or without expression of SHP. In the 
absence of exogenous SHP, G9a had little effect on the HNF-4/PGC-la transactivation 
(Fig. 3C, lanes 6-8) while increasing inhibition was observed with SHP (lanes 3-5), 
suggesting that SHP is required for the inhibitory effect of G9a. We also tested if G9a 
enhances SHP inhibition of HNF-4-mediated transactivation of the natural CYP7A1 
promoter rather than the Gal4 reporter used above. Exogenous expression of SHP 
inhibited HNF-4 transactivation of CYP7A1 promoter activity and cotransfection of 
increasing amounts of G9a vector potentiated the SHP inhibition in a dose-dependent 
manner in Cos-1 cells while expression of G9a in the absence of SHP had much lesser 
effects (Fig. 3D). Transfection of increasing amounts of G9a also potentiated the 
inhibition of CYP7A1 promoter activity by exogenously expressed SHP in HepG2 cells 
(not shown). These functional reporter studies suggest that G9a cooperatively enhances 
inhibition of CYP7A1 transcription with SHP.
O v e r e x p r e s s io n  o f  G9a-DN re v e rs e s  CYP7A1 in h ib i t io n  in  b i le  a c id - t r e a t e d  H e p G 2  
cells
It has been shown that bile acid treatment results in the induction of SHP, which inhibits
expression of CYP7A1 in HepG2 cells and in animals in vivo (8, 9, 15, 24, 31). To
evaluate the role of G9a in the suppression of the CYP7A1 promoter activity mediated by
bile acid-induced SHP, HepG2 cells, in which CYP7A1 promoter-luciferase reporter
plasmid DNA is stably incorporated into the genome, were infected with either Ad-empty
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or Ad-G9a-DN and 2 days later, cells were treated with 25 or 50 }iM of a primary bile 
acid, chenodeoxycholic acid (CDCA) and reporter activity was measured. Luciferase 
activity was inhibited about 30% and 40% by 25 and 50 CDCA treatment, 
respectively, (Fig. 3E, lanes, 1, 2, 5) and infection with the increasing amounts of Ad- 
G9a-DN completely reversed the inhibition (lanes, 3, 4, 6, 7). We further tested if 
expression of G9a-DN reversed the SHP-mediated inhibition of endogenous CYP7A1 
gene expression after bile acid treatment. HepG2 cells were infected with Ad-empty or 
Ad-G9a-DN, and 2 days after infection, cells were treated with 25 jiM of CDCA. 
Levels of the endogenous CYP7A1 mRNA in HepG2 cells were measured by 
quantitative real time RTPCR. After CDCA treatment, CYP7A1 mRNA levels were 
decreased about 50% and infection of HepG2 cells with Ad-G9a-DN completely reversed 
the decrease (Fig. 3F). These results indicate that G9a is involved in SHP-mediated 
suppression of endogenous CYP7A1 expression, most likely, by catalyzing H3K9 
methylation at the native promoter in bile acid-treated HepG2 cells.
G 9 a  is r e c r u i t e d  to  th e  e n d o g e n o u s  C Y P 7 A 1  a n d  C Y P 8 B 1  p r o m o t e r s  a n d  H 3 K 9  is 
m e t h y l a t e d  in  m ice  fed  cho lic  ac id  a n d  in b ile  a c id - t r e a t e d  H e p G 2  cells
If the interaction of G9a with SHP is physiologically relevant for bile acid metabolism, 
then G9a should be recruited to the transcriptionally suppressed promoters of the SHP 
target genes, Cyp7al and Cyp8bl, in mice fed cholic acid. In mice fed chow containing
0.5% cholic acid for 24 hr, SHP mRNA levels were increased, whereas Cyp7al and 
CypSbl mRNA levels were substantially decreased as determined by real time RTPCR 
(Fig. 4A). In mice fed cholic acid, increased association of SHP with the promoters of
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the hepatic Cyp7al and Cyp8bl genes was detected by chromatin immunoprecipitation 
(ChIP) assays compared to mice fed normal chow (Fig. 4B, C). In addition, increased 
association of G9a was observed in these mice (Fig. 4B, C). These results indicate that 
both SHP and G9a are recruited to these promoters in response to increased bile acid 
levels which is consistent with a functional interaction between SHP and G9a.
We previously reported that bile acid treatment resulted in a decrease in the 
acetylation of H3 and H4 at the human CYP7A1 promoter in HepG2 cells but did not 
determine whether H3K9 was the modified residue (24). Further, since the recruitment 
of G9a to the Cyp7al and Cyp8bl promoters was increased after bile acid treatment and 
methylation of H3K9 has been inversely correlated with acetylation at H3K9 and H3K14 
(27, 41, 43), it seemed likely that methylation of H3K9 should also increase. Therefore, 
these histone modifications were examined by ChIP assay using antisera specific for 
either dimethyl H3K9 or diacetyl H3K9/K14. In mice fed cholic acid, Cyp7al and 
Cyp8bl promoter sequences precipitated by antisera against diacetyl H3 K9/K14 were 
substantially decreased, while the promoter sequences precipitated by antisera against 
dimethyl H3K9 were markedly increased (Fig. 4B, C). The control GAPDH coding 
region was not precipitated by any of the antisera. These results indicate that H3K9 at 
the Cyp7al and Cyp8bl promoters is deacetylated and then methylated in livers of mice 
fed cholic acid.
We also examined the effects of treatment of HepG2 cells with CDCA. 
CDCA treatment markedly increased SHP mRNA levels and decreased CYP7A1 mRNA 
levels in HepG2 cells (Fig. 4D). ChIP assays showed that CDCA treatment increased 
recruitment of SHP and G9a, decreased H3K9 acetylation, and increased H3K9
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methylation at the promoters of CYP7A1 and CYP8B1 (Fig. 4E, F), which is consistent 
with the studies above on mice fed cholic acid (Fig. 4B, C). These studies in vivo in 
mice led cholic acid and in bile acid-treated HepG2 cells establish that endogenous SHP 
and G9a are recruited to the transcriptionally repressed native CYP7A1 and CYP8B1 
promoters. Consistent with this recruitment, and that of HDACs observed previously 
(24), H3K9 at the native CYP7A1 and CYP8B1 promoters is deacetylated and 
methylated.
G 9 a  r e c r u i t m e n t  a n d  s u b s e q u e n t  H 3 K 9  m e th y la t io n  a f t e r  b ile  a c id  t r e a t m e n t  is 
d e p e n d e n t  o n  S H P  ex p re s s io n
To determine if SHP is directly involved in the recruitment of G9a and subsequent H3K9 
methylation at the native CYP7A1 promoter after bile acid treatment, HepG2 cells were 
either transiently transfected with pSuper-siSHP (24) or infected with adenoviral vector 
encoding human SHP siRNA (Ad-siSHP). Treatment of HepG2 cells with CDCA 
increased and decreased mRNA levels of SHP and CYP7A1, respectively (Fig. 5A). 
Transient transfection of SHP siRNA vectors significantly reversed the changes in 
mRNA for SHP and CYT7A1 after CDCA treatment which is consistent with previous 
studies (24).
As determined by ChIP assay, SHP was recruited to the native CYP7A1 
promoter by CDCA treatment but the recruitment was decreased in cells transiently 
transfected with pSuper-siSHP or infected with Ad-siSHP and association Oi G9a with 
the promoter w7as also reduced in these cells (Fig. 5B, C). The state of histone 
methylation and acetylation was examined in the adenoviral infected cells. The
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decrease in histone acetylation and increase in methylation at H3K9 observed after bile 
acid treatment were markedly reversed in the cells infected with Ad-siSHP (Fig. 5C). 
These results suggest that recruitment of G9a to the native CYP7A1 promoter and 
subsequent H3K9 methylation are contingent on expression of bile acid-induced SHP. 
These results, together with in vitro protein interaction studies (Fig. 1), suggest that G9a 
is recruited by SHP to CYP7A1 promoter after bile acid treatment, probably by direct 
interaction with SHP.
B lo c k in g  th e  H 3 K 9  m e th y la t io n  b y  G 9 a -D N  p a r t i a l l y  in h ib i t s  h i s to n e  d e a c e ty lk t io r  
a t  t h e  C Y P 7 A 1  p r o m o t e r  c h r o m a t in
Methylated H3K9 by G9a could serve as a binding platform to recruit SHP-associated 
chromatin modifying complexes for transcriptional silencing. For example, it has been 
suggested that H3K9 methylation affects deacetylation by enhancing recruitment and/or 
activity of HDACs and by inhibiting the association and/or the activity of HATs (41, 43, 
44). Therefore, to test if inhibition of H3K9 methylation at the CYP7A1 promoter 
affects deacetylation at H3K9, HepG2 cells were infected with either Ad-G9a-DN or Ad- 
empty, treated with CDCA, and analyzed by ChIP assays using antibodies against either 
dimethylated H3K9 or diacetylated H3K9/K14. In addition, the infected cells were 
subjected to real time RTPCR to analyze effects of G9a-DN on CYP7A1 expression. 
After CDCA treatment, CYP7A1 mRNA levels were decreased about 70% and infection 
of HepG2 cells with Ad-G9a-DN partially but significantly reversed the decrease (Fig.
6A).
CYP7A1 promoter chromatin precipitated with the dimethylated H3K9
antibody was increased after CDCA treatment in cells infected with Ad-empty (Fig. 6B,
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C), as expected from ChIP studies with uninfected cells (Fig. 4, 5). However, in 
CDCA-treated HepG2 cells infected with Ad-G9a-DN, methylation was reduced about 
50% (Fig. 6B, C). The control GAPDH coding region was not precipitated by any of 
the antisera (not shown). I hese results indicate that increased dimethylation of H3K9 at 
the native CYP7A1 promoter after CDCA treatment is dependent on G9a activity.
CYP7A1 promoter sequence precipitated with diacetylated H3K9/K14 
antibody was reduced about 80% after CDCA treatment in cells infected with Ad-empty 
(Fig. 6B, C) as expected from studies with uninfected cells (Fig. 4, 5). However, the 
amount of precipitated promoter DNA was markedly increased about 2-fold in CDCA- 
treated cells infected with Ad-G9a-DN compared to cells infected with Ad-empty 
although this increase was just short of statistical significance (Fig. 6B, C). These 
results indicate that inhibition of the endogenous G9a by G9a-DN inhibited H3K9 
methylation as expected, but also partially blocked diacetylation of H3K9. These results 
are consistent with the idea that acetylation of H3K9 is decreased after CDCA treatment 
even if methylation is blocked by recruitment of HDACs and possibly dissociation of 
HATs. Methylation by G9a may block re-acetylation of H3K9, resulting in nearly 
complete deacetylation.
In  b i le  a c id - t r e a t e d  H e p G 2  cells, A d -G 9 a -D N  b lo c k s  r e c r u i t m e n t  o f  th e  S w i/S n f-  
B r in  c o m p le x ,  b u t  n o t  o f  H D A C - c o n ta in in g  c o r e p r e s s o r  c o m p le x e s ,  to  t h e  C Y F 7 A 1 
p r o m o t e r
Since blocking methylation partially reversed deacetylation, it is possible that 
methylation is required for recruitment of chromatin modifying complexes, such as
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HDAC corepressor and the Swi/Snf-Brm chromatin remodeling complexes to the native 
C \  P7A1 promoter. I o examine this question, HepG2 cells were infected with either 
Ad-G9a-DN or Ad-empty, treated with CDCA, and subjected to ChIP assays using 
antibodies against mSin3A, HDAC-1, HDAC-2, NcoRl, HDAC-3, BAF170, or Brm. 
CY P7A1 promoter sequences precipitated with antibodies against all these cofactors were 
increased in HepG2 cells infected with Ad-empty after CDCA treatment, indicating that 
corepressor mSin3A/HDAC-l/2, corepressor NcoRl/HDAC3, and the Swi/Snf-Brm 
remodeling complexes are recruited after CDCA treatment (Fig. 6D, E) as previously 
shown (24). CYP7A1 promoter sequences precipitated with antibodies against mSin3A, 
HDAC-1, HDAC-2, NcoRl, or HDAC-3, were not reduced in HepG2 cells infected with 
Ad-G9a-DN, suggesting that recruitment of these corepressor complexes is not dependent 
on dimethylation at H3K9 even though deacetylation is partially blocked. The amounts 
of the CYP7A1 promoter sequence precipitated with antibodies against Brm or BAF 170 
were reduced about 50% in cells infected with Ad-G9a-DN (Fig. 6D, E). These results 
suggest that G9a is critical for the inhibitory SHP action by catalyzing dimethylation of 
H3K9, which prevents reversible acetylation thereby “locking” H3K9 in a deacetylateu 
state and is prerequisite for recruitment of the Brm complex, which in turn catalyzes 
chromatin remodeling, ultimately resulting in transcriptional silencing of the CYP7A1 
gene.
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I n h i b i t i o n  o f  HDAC ac t iv i ty  by  TSA b locks  H 3 K 9  m e th y la t io n  b u t  n o t  r e c r u i t m e n t  
o f  G 9 a  to  t h e  CYP7A1 p r o m o t e r
Histone deacetylation and methylation are coordinated events and are functionally 
associated with gene silencing (19, 27). H3K9 deacetylation is required in order for 
methylation to occur at H3K9, but it is not clear whether deacetylation is required for the 
recruitment of the G9a methyltransferase. To examine this question, the effect of TSA, 
an inhibitor of HDAC activity, on bile acid-induced chromatin modification and G9a 
recruitment in HepG2 cells was examined. First, to examine the functional correlation 
between histone deacetylation and methylation, Cos-1 cells were cotransfected with a 
Gal4-TATA-luc reporter and expression plasmids for Gal4DBD-HNF-4, PGC-la, SHP, 
and G9a and the transfected cells were treated with increasing amounts of TSA. 
Expression of SHP reduced transactivation mediated by HNF-4/ PGC-la and 
coexpression of G9a further enhanced the SHP inhibitory activity (Fig. 7A, lanes, 1-3). 
Increasing amounts of TSA completely reversed the inhibitory effects of SHP and G9a on 
the reporter activity in a dose-dependent manner (lanes, 4-7).
To assess the effects of TSA on bile acid regulation of endogenous CYP7A1 
expression, cells were pretreated with TSA and then additionally treated with CDCA. 
Treatment with CDCA suppressed CYP7A1 mRNA levels by about 50% (Fig. 7B). 
Treatment with TSA resulted in a complete reversal of the decreased in CYP7A1 mRNA 
levels, indicating that histone deacetylation is important for the suppression of CYP7A1
expression by bile acids.
In ChIP assays under the same experimental conditions described in Fig. 7B, 
addition of TSA reversed the decrease in diacetylation and the increase in dimethylation
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at 11310 after bile acid treatment (Fig. 7C, D). Interestingly, TSA treatment did not 
reduce the amount of CYP7A1 promoter sequence precipitated by G9a antibody in the 
bile acid-treated cells, indicating that G9a recruitment to the promoter was not dependent 
on deacetylation (Fig. 7C, D). In contrast, the control GAPDH coding region was not 
precipitated by any oi the antisera (not shown). This result is consistent with the studies 
above indicating that both HDACs and G9a are recruited to the CYP7A1 promoter by 
bile acid-induced SHP.
Results from ChIP assays and these functional reporter assays suggest that 
histone deacetylation by HDACs at H3K9 is required for dimethylation by G9a and 
conversely, dimethylation by G9a is important in HDAC-mediated deacetylation and 
transcription suppression. These results further suggest that recruitment and activity of 
chromatin modifying cofactors including G9a and HDACs are coordinated and inter­
dependent events in the transcriptional silencing of CYP7A1 mediated by bile acid- 
induced SHP.
A c u te  l iv e r -sp e c i f ic  in h ib i t io n  o f  G 9 a  d i s ru p t s  b i le  ac id  h o m e o s ta s i s  a n d  p a r t i a l l y  
r e v e r s e s  s u p p r e s s i o n  o f  C v p 7 a l  a n d  C v p 8 b l  genes in  m ice  in  v ivo
To determine the in vivo significance of G9a in the SHP-mediated negative feedback 
inhibition of hepatic bile acid metabolism, the activity of G9a in mouse liver was 
inhibited by the expression of G9a-DN. Mice were injected with Ad-G9a-DN or Ad- 
empty virus via the tail vein. Three days later, mice were fed either normal or 0.5% 
cholic acid-supplemented chow for 5 hr or 24 hr and then the liver, gall bladder, and 
small intestine were collected for lurther analyses. Expression of G9a-DN in the liver was
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confirmed by western blotting and similar infection efficiencies of over 80% between 
experimental groups were observed based on GFP expression (not shown).
First, to ensure that G9a-DN expressed in mouse liver blocked endogenous G9s* 
activity, liver extracts were prepared from mice infected with Ad-G9a-DN or Ad-empty 
virus and immunoprecipitated with SHP antibody or control IgG. Then, the 
immunoprecipitates were incubated with purified GST-H3 (1-84) or GST-H3R9 mutant 
as histone substrates in an in vitro HMT assay. The control IgG immunoprecipitates did 
not show any HMT activity (Fig. 8A). In contrast, hepatic SHP complex 
immunoprecipitated from mice infected with Ad-empty methylated GST-H3 (1-84), 
whereas the complex from mice infected with Ad-G9aDN did not methylate GST-H3 (1- 
84) (Fig. 8A) consistent with the results obtained with HepG2 cells (Fig. 2F). These 
results indicate that overexpression of G9a-DN inhibited H3K9 methylation by blocking 
endogenous G9a activity present in the hepatic SHP complex.
To determine if blocking hepatic G9a activity by G9a-DN affects bile acid 
homeostasis, we measured the total bile acid pool size in mice infected with either Ad- 
empty or Ad-G9a-DN. Bile acid pools in these two groups were similar when fed with 
normal chow (Fig. 8B). In contrast, the total bile acid pools were slightly elevated in 
mice fed cholic acid for 5 hr and significantly increased by 2-fold after 24 hr in mice 
infected with Ad-G9a-DN compared to those infected with Ad-empty (Fig. 8B).
To better understand the molecular basis of elevated bile acid pools in mice 
expressing G9a-DN, we examined effects of G9a-DN on the mRNA levels of the SHP 
target genes in bile acid biosynthesis, Cyp7al and Cyp8bl. As expected, in uninfected 
mice fed 0.5% cholic acid-supplemented chow, the levels of mRNA for Cyp7al and
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Cyp8bl were decreased about 50% after 5 hr of feeding (Fig. 8C) and about 80% after 24 
lit oi ieeding (Hg. 8D). In mice infected with Ad-empty, similar effects were observed 
although the inhibition at 5 hr was greater than in the uninfected controls (Fig. 8C, D). 
Interestingly, at 5 hr, suppression of Cyp7al in the Ad-G9a-DN mice fed cholic acid was 
significantly reversed compared to the Ad-empty group, while at 24 hr of cholic acid 
feeding, a modest nonsignificant reversal was observed (Fig. 8C, D). Compared to 
regulation ot Cyp7al, suppression of Cyp8bl was modestly, but significantly, reversed in 
the Ad-G9a-DN mice after 5 hr of feeding, although the difference was not significant at 
24 hr (Fig. 8C, D). SHP mRNA levels, as expected, were increased after bile acid 
feeding in all groups at 5 hr and more dramatically at 24 hr (Fig. 8C, D). Compared to 
the Ad-empty mice, SHP mRNA levels in the Ad-G9a-DN mice after cholic acid feeding 
was slightly reduced, but the changes were not statistically significant. These results 
indicate that inhibition of endogenous G9a activity by G9a-DN elevated the total bile 
acid pool size which in part may be caused by transient reversal of suppression of 
Cyp7al and Cyp8bl expression by bile acid feeding.
These in vivo animal studies, along with the studies in HepG2 cells and in vitro 
mechanistic studies, establish a physiological role of G9a as a key downstream cofactor 
of the bile acid-activated SHP pathway resulting in acute transcriptional suppression of 
Cyp7al and Cyp8bl genes.
Discussion
In this paper we present evidence that G9a plays a critical role in the SHP-mediated 
suppression of hepatic bile acid biosynthesis, by catalyzing H3K9 methylation at the
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CYI 7A1 and CYP8B1 promoters which is required for recruiting the Swi/Snf-Brm 
complex and transcriptional silencing. Our major findings to support this conclusion are 
as follows, endogenous G9a was associated with SHP in mouse liver and HepG2 cells, 
and G9a in hepatic SHP complexes methylated H3K9 in vitro. SHP and G9a were 
recruited to the native C \ P7A1 and CYP8B1 promoters after bile acid treatment and 
recruitment of G9a and subsequent H3K9 methylation were impaired if SHP expression 
was reduced by siRNA, indicating that SHP is required for G9a recruitment. G9a 
expression enhanced the inhibition of CYP7A1 transcription by SHP which was 
correlated with the methylation of H3K9 by G9a. Inhibition of G9a activity by 
expression of G9a-DN in HepG2 cells inhibited H3K9 methylation after bile acid 
treatment and partially reversed bile acid-mediated suppression of the endogenous 
CYP7A1 gene expression. Interestingly, expression of G9a-DN also partially reversed 
deacetylation of H3K9 and blocked recruitment of the Brm complex to the promoter, 
indicating that deacetylation and methylation were required for recruitment of the Brm 
complex and ultimately for transcriptional silencing. Acute liver-specific inhibition of 
G9a by G9a-DN elevated the total bile acid pool size in mice fed cholic acid and partially 
de-repressed Cyp7al and Cyp8bl, indicating bile acid homeostasis was disrupted. 
These results establish a critical role for G9a in the SHP-mediated suppression of Cyp7al 
and Cyp8bl in cholesterol/bile acid metabolism.
From chromatin immunoprecipitation studies in mouse liver and in HepG2 cells, 
we observed that SHP was recruited to the native CYP7A1 promoter in mice fed cholic 
acid and CDCA-treated I IepG2 cells (Fig. 4). Acetylation of histones H3 and H4 and 
specific acetylation of H3K9 were markedly decreased and H3K9 methylation was
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substantially increased after feeding mice cholic acid or treating HepG2 cells with bile 
acids, consistent with recruitment of HDACs and G9a. Consistent with our 
observations, a recent study showed that SHP was detected at the Cyp7al, as well as 
( yp8bl, promoter in transgenic mice expressing SHP in the liver at levels equivalent to 
those observed after feeding cholic acid (5). Interestingly, chromatin changes at these 
two promoters differed in that study. In contrast to our observations, HDACs and 
changes in histone acetylation and methylation were not detected at the Cyp7al promoter 
in the transgenic mice, while in parallel to our studies, histone acetylation was decreased 
and H3K9 methylation was increased at the Cyp8bl promoter. This discrepancy for 
Cyp7al may result from the length of time that SHP was elevated in the two systems. 
Our studies were done in a transient acute setting to assess direct effect of bile acids on 
the association of regulatory proteins with the native promoters, whereas in the transgenic 
animal model, high levels of SHP were sustained continuously in the liver, which may 
lead to secondary effects that affect regulation of Cyp7al expression, but not that of 
Cyp8bl. Differential responses to different lengths of cholic acid feeding were also 
observed in our in vivo study. Suppression of Cyp7al was substantially reversed in the 
Ad-G9a-DN mice after 5 hr of cholic acid feeding compared to the control Ad-empty 
mice, while the reversal was very modest at 24 hr. Suppression of Cyp8bl was only 
modestly reversed at both time points suggesting that regulation of these two genes is not 
identical which has also been observed with long cholic acid feeding times in SHP-null 
mice (47). These results imply that at longer times of cholic acid feeding, the influence 
of the FXR/SHP pathway on Cyp7al regulation may decrease and SHP-independent 
pathways may become predominant. This interpretation is consistent with the trends
56
observed in previous SHP-null mice studies in which Cyp7al was still mostly repressed 
after 1 week of cholic acid feeding, whereas it was almost completely reversed 1 day 
after cholic acid feeding. These studies were interpreted to suggest that the FXR/SHP 
pathway was more important acutely after cholic acid feeding (25, 47-49). In our 
studies, however, at 24 hr after cholic acid feeding, the reversal of Cyp7al expression 
was already largely lost. One interpretation of this result is that the role of G9a is even 
more transient than that of SHP/FXR in the suppression of Cyp7al. A second is that 
inactivation of G9a will have effects on the activity of multiple transcription factors, in 
addition to SHP, which might have indirect effects on Cyp7al expression not observed in 
the SHP-null mice. Nevertheless these data are consistent with an important role for 
G9a in the acute regulation of Cyp7al in vivo. This is consistent with an increase in bile 
acid pools although other factors probably also contribute to the increased pool size.
H3K9 methyltransferase enzymes can be recruited to the target promoters by 
direct interaction with gene-specific DNA binding proteins or with non-DNA binding 
corepressors. For instance, G9a has been shown to interact with PRD-BF1, CtBP, 
CDP/cut, Gfil, and SHP and is mainly responsible for silencing of target genes in the 
euchromatin region (6, 12, 16, 36, 43). SHP was also shown to be localized exclusively 
with nuclease-sensitive euchromatin and not with the heterochromatic DNA binding 
protein HP1 (6). Consistent with these findings, we observed that SHP and the 
euchromatic methyltransferase, G9a, but not the heterochromatic methyltransferase, 
SUV39H1, were colocalized in the nucleus (Fig. 1). Further, inhibition of CYP7A1 
transcription by SHP was increased by expression of G9a, but not by expression of 
SUV39H1 (Fig. 3). Interestingly, SHP, like other inhibitory factors, interacts with G9a
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and corepressor HDACs through distinct domains, its N-terminal and C-terminal 
domains, respectively (6, 24). These results suggest that SHP could recruit both HDAC- 
containing corepressor complexes and G9a to the native CYP7A1 promoter 
simultaneously.
Although the role of H3K9 methylation by G9a has been established in 
epigenetic gene silencing, little is known about how this enzyme is recruited and 
coordinately works with other chromatin modifying cofactors at the native target 
promoters. Inhibition of SHP expression by siRNA in HepG2 cells demonstrated that 
G9a recruitment to the CYP7A1 promoter and subsequent H3K9 methylation is 
contingent on SHP expression (Fig. 5). Since we, and others (6), have shown that SHP 
can interact with G9a, the simplest conclusion from these SHP siRNA studies is that G9a 
recruitment is mediated by a direct interaction with SHP. The siRNA data, however, do 
not eliminate the possibility that G9a is recruited indirectly by another SHP-dependent 
protein. Inhibition of H3K9 deacetylation by a specific HDAC inhibitor, TSA, inhibited 
the H3K9 methylation at the promoter chromatin, but interestingly, did not inhibit 
recruitment of G9a (Fig. 7). The recruitment of G9a alone, therefore, was not sufficient 
for methylation at H3K9 but required previous deacetylation at H3K9. Functional 
reporter assays showed that G9a increased SHP inhibition of transactivation mediated by 
HNF-4/PGC-1 a, but these effects were blocked by TSA. These results suggest a central 
role of histone deacetylation in mediating the transcriptional repression either directly, or 
indirectly, by permitting G9a-mediated methylation. Coordinated sequential 
modification of deacetylation and methylation ot H3K.9 have been shown in other 
systems as well, for example, the CtBP corepressor complex in oncogenesis (41), Gfil in
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the regulation of development and oncogenesis (12), PRDI-BF1 in interferon B gene 
transcription (16), and HP1 recruitment for gene silencing (34, 43).
Conversely, H3K9 deacetylation at the CYP7A1 promoter after bile acid 
treatment was markedly affected by inhibition of H3K9 methylation by G9a-DN, whereas 
the recruitment of HDACs-containing corepressor complexes was not affected (Fig. 7). 
Methylation appears to be required to “lock” the H3K9 in a deacetylated state and 
prevent reversible acetylation rather than for recruitment of HDACs. Interestingly, 
deacetylation and methylation at H3K9 are required for recruitment of the Brm 
remodeling complex during transcriptional silencing of CYP7A1 (Fig. 6). Therefore, 
these results collectively suggest that recruitment and activity of chromatin modifying 
cofactors are temporally coordinated sequential events in SHP-mediated repression of 
CYP7A1.
Based on the in vitro, in vivo and cell culture results, we propose a model for 
SHP-mediated active suppression of CYP7A1 transcription (Fig. 9). As proposed 
earlier (20, 21, 29), bile acid-induced SHP may compete with coactivator HATs, 
including p300, CBP, and SRC-1, for binding at the target promoters initially. SHP then 
directly interacts with HDAC-containing mSin3A and NcoRl corepressor complexes and 
G9a methyltransferase through its C-and N-terminus, respectively, recruiting these 
factors to the promoter, which results in deacetylation and subsequent dimethylation. 
Deacetylation of H3K9 is required for methylation and conversely, methylation of H3K9 
is also required to prevent reversal ot the deacetylation. H3K9 methylation and 
deacetylation create a binding surface for the Swi/Snf-Brm complex which allows the 
SHP-dependent recruitment of this remodeling complex to the CYP7A1 promoter. The
Swi/Snf complex then catalyzes the ATP-dependent remodeling of the promoter 
chromatin as demonstrated previously (24), which establishes a transcriptionally 
suppressed chromatin structure. These coordinated biochemical and enzymatic events 
at the native CY P7A1 promoter help convert the chromatin from an active to a repressed 
state which underlies the feedback inhibition of bile acid synthesis by SHP.
In Jhe present and previous studies, we demonstrated that chromatin modifying 
enzymes, such as histone deacetylases, G9a histone methyltransferase, and Swi/Snf-Brm, 
are critical downstream cofactors in mediating SHP activity in the regulation of hepatic 
cholesterol/bile acid metabolism (24). Abnormal SHP function has been implicated in 
metabolic disorders such as hypercholesterolemia, cholestasis, obesity, and diabetes (2). 
Interestingly, heterozygous mutations of the SHP gene in humans are associated with a 
predisposition for moderate obesity and diabetes (35). Therefore, it will be interesting 
to test whether these naturally occurring SHP mutants show an impaired ability to recruit 
these chromatin modifying enzymes to target genes. Aberrant regulation of histone 
methylation and deacetylation is now emerging as a major contributor to carcinogenesis, 
and molecules that affect epigenetic regulation, such as HDAC inhibitors, are now 
actively being tested as therapeutic agents (17). In this regard, modulation of SHP 
function by targeting these chromatin modifying enzymes may help lead to new 
pharmacological agents for metabolic disorders.
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Fig. 1. G 9 a  a s s o c ia te s  w i th  S H P  in m ouse l iv e r  a n d  H e p G 2  cells. (A, B) SHP and
G9a (A), but not SIJV39H1 (B), colocalize in the nucleus. Cos-1 cells were 
cotransfected with expression plasmid DNA for GFP-SHP and either G9a or HA- 
SUV39H1. SHP was detected by GFP fluorescence (green) and G9a and SUV39H1 
were detected by immunofluorescence using Rhodamine-conjugated secondary' Ab 
(red) as described in Materials and Methods. Representative confocal microscopic 
images for G9a or SUV39H1 immunofluorescence (left), green fluorescent images 
for GFP-SHP (center), and merged images (right) are shown. The yellow regions in 
the merged images indicate colocalization of G9a and SHP. (C) Nuclear extracts 
were prepared from mouse liver or HepG2 cells and incubated with GST or GST- 
SHP. The GST proteins were bound to glutathionine-Sepharose, and after washing, 
proteins associated with the GST proteins were detected by SDS-PAGE and western 
blotting using G9a antibody. The position of G9a is indicated and positions of 
molecular weight markers are indicated at the left. The input contains 10% of the 
amount of extract used in the binding reactions. (D). Nuclear extracts prepared from 
HepG2 cells were immunoprecipitated using IgG as a control or with antibody 
against SHP or G9a and association of endogenous G9a or SHP in the 
immunoprecipitates was detected by SDS-PAGE and western blotting using G9a or 
SHP antibodies, respectively. The diffuse bands for G9a compared to those in (C) 
result from the large amount of protein from the precipitating antibody in the sample 
which reduces the resolution of the bands. (E). Schematic diagrams of SHP and full 
length (FL) GST-SHP, and GST-SHP deletion mutants. RID and RD refer to 
receptor interacting and intrinsic repression domains, respectively. (F). 35S-G9a was 
synthesized in vitro, and GST pull down assays were performed as described in 
Materials and Methods. The input represents 20% ol the S-labeled G9a used in the 
binding reactions. The position ot G9a is indicated. (G). A schematic diagram ot the 
GST-G9a deletion mutant (621-1000). SET indicates a domain common to Su (vw). 
Enhancer o f Zeste, and Trithorax. (H). 35S-SHP was synthesized and GST pull down 
assays were performed as described in I\ lhe input represents 20% of the S- 
labeled SHP used in the reactions.
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extracts from HepG2 cells or mouse liver were incubated with bacterially expressed, 
purified GST-SHP or GST that had been bound to glutathione-Sepharose. The 
proteins associated with GS T-SHP or GST were used as the source of enzyme in in 
vitro HMT assays. Proteins were separated by SDS-PAGE, followed by Coomassie 
staining (lower panel) of the gels and autoradiography (upper panel). The positions of 
histones H3 and H4 are indicated. (B). Mouse liver nuclear extracts were incubated 
with bacterially expressed, purified GST-SHP or GST that had been bound to 
glutathione-Sepharose. The proteins associated with the Sepharose beads were used 
as the source of enzyme in HMT assays. After the reaction, proteins were separated 
by SDS-PAGE and dimethylated H3K9 histones were detected by western blotting 
using dimethylated H3K9 antibody. The position of a molecular weight marker is 
shown at the left. The position of H3 (dimethyl H3K9) is indicated at the right. (C). 
HepG2 nuclear extracts were immunprecipitated with either SHP antibody or control 
IgG and the immunoprecipitates were used as the source of enzyme in HMT assays. 
The proteins were separated by SDS-PAGE and then by Coomassie staining of the 
gels to detect the amounts of core histone substrate used in the assay (lower panel), 
followed by autoradiography to detect 3H-labeled histones (upper panel). The position 
of histones H3 and H4 are indicated. (D-F). (D). Experimental outlines: HepG2 cells 
were infected with control empty adenoviral vector (Ad-empty) or adenoviral vector 
encoding G9a-DN (Ad-G9a-DN) and 36 hr later, the infected cells were subjected to 
semi-quantitative RTPCR, western blotting (E) or immunoprecipitation followed by in 
vitro HMT assays (F). (E). Cell extracts were subjected to western blotting using G9a 
antibody and I INF-4 antibody as a control. (F). Cell extracts were 
immunoprecipitated with SHP antibody or control IgG, and the immunopreciptates 
were used as the source ol enzyme in in vitro HMI assays. Bacterially-expressed and 
purified GST-H3 (1-84) (WT) or a GST-H3 mutant (H3R9) in which K9 is mutated to 
Arg as shown w;as used as histone substrates. I he HMT reaction samples were 
analyzed as described in A.
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Fig. 3, cont. G9a enhances SHP inhibition of CYP7A1 transcription. (A). Cos-1 cells 
were cotransfected with 200 ng of 5Gal4-TATA-luc, 300 ng of CMV-B-gal, and 50 ng of 
Gal4DBD (G4DBD) or Gal4-HNF-4 (G4HNF-4), 100 ng of pcDNA3-PGC-la, and 
increasing amounts of pcDNA3-SHP and pEGFP-hG9a as indicated. (B). Cos-1 cells were 
cotransfected with 200 ng of 5Gal4-TATA-luc, 300 ng of CMV-B-gal, 50 ng of Gal4- 
HNF-4, 50 ng oi pcDNA3-PGC-la, 25 ng of SHP, and increasing amounts of either 
pcDNA3-G9a or pcI)NA3.1-SUV39Hl. (C). Cos-1 cells were cotransfected with 200 ng 
of 5Gal4-TATA-luc, 300 ng of CMV-B-gal, 10 ng of Gal4-HNF-4, 5 ng of pcDNA3-PGC- 
la , 25 ng of pcDNA3-SHP, and increasing amounts of pcDNA3-G9a as indicated. (D). 
Cos-1 cells were cotransfected with 200 ng of 5Gal4-TATA-luc, 300 ng of CMV-B-gal, 
200 ng of - 1 887-hCYP7A1 -luc, 50 ng of CMV-HNF-4, 25 ng of pcDNA3-SHP, and 
increasing amounts of pEGFP-G9a as indicated. In each case (A-D), the values for firefly 
luciferase activities were normalized by dividing by B-galactosidase activities. S.E.M. was 
calculated from triplicate determinations. Consistent results were obtained from 2-4 
independent triplicate assays. (E). HepG2 cells in which -1887 hCYP7Al-luc reporter 
plasmid DNA was stably incorporated into the genome were infected with Ad-G9a-DN or 
Ad-empty, and 24 hr after infection, cells were treated with 25 or 50 pM CDCA or vehicle 
for 10 hr. Firefly luciferase activities were determined and normalized by dividing by 
total protein amounts. The S.E.M. was calculated from triplicate samples and statistical 
significance was determined by the Student’s t-test. * indicates p < 0.05 and NS refers to 
statistically not significant. (F). HepG2 cells were infected with Ad-G9a-DN or Ad-empty 
and 24 hr after infection, cells wrere treated with 25 pM CDCA or vehicle for 10 hr. Total 
RNA was isolated and subjected to real time RTPCR. CYP7A1 mRNA levels were 
normalized to B-actin mRNA levels and the S.E.M. w^ as calculated from triplicate samples. 
Differences between Ad-empty and Ad-G9a-DN samples in CDCA-treated samples w'ere 
analyzed by the Student t-test. * indicates p < 0.05.
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Fig. 4, cont. (>9a is recruited to the endogenous CYP7A1 and CYP8B1 promoters and 
H3K9 is methylated in mice fed cholic acids and in CDCA-treated HepG2 cells. Mice 
were led normal or 0.5% cholic acid (C.A.)-supplemented chow for 24 hr and livers were 
collected lor real time R I PCR or ChIP assays. (A). Total RNA was isolated from mouse 
liver and subjected to RTPCR using primers specific to mouse Cyp7al, Cyp8bl, SHP, and 
36B4 as a control, as described in Materials and Methods. (B) At the top, schematic diagrams 
of mouse Cyp7al, Cyp8bl, and GAPDH genes with the positions of the primers used for the 
PCR reactions are shown. Soluble chromatin was isolated and pre-cleared as described in 
Materials and Methods and immunoprecipitated with antibodies against SHP, G9a, 
diacetylated H3 K9/K14 (di-AcH3 K9/K14), or dimethylated H3K9 (di-Met H3K9), or with 
normal serum (NS). Precipitated chromatin was extensively washed. Genomic DNA was 
isolated from the input chromatin before precipitation (total) or from the precipitated 
chromatin and was analyzed by semi-quantitative PCR using primer sets specific for Cyp7al, 
Cyp8bl, and GAPDH. (C) The intensities of bands were determined using Image J program. 
The amount of Cyp7al promoter sequence precipitated by each antibody was normalized by 
dividing by the amount of the promoter sequence in the input DNA sample, and the value in 
the control group for each factor were assigned as a value of 100%. (D-F). HepG2 cells 
treated with 50 JJM CDCA or vehicle DMSO in serum-free media for 18 hr were collected 
for real time RTPCR (D) and ChIP assays (E,F). (D). Total RNA w7as isolated and subjected 
to real time RTPCR using primers specific to human CYP7A1, SHP, and 36B4 as a control. 
(E). At the top, a schematic diagram of the human CYP7A1 gene and the position of the 
primer set specific for CYP7A1 used for semi-quantitative PCR are shown. ChIP assays 
were performed using antibodies against SHP, G9a, acetylated histone H3, diacetylated H3 
K9/K14, or dimethylated H3K9, or using normal serum (NS). (F) Results were quantified 
and analyzed from three experiments as described for panel C. (A-F). The S.E.M. is 
calculated from triplicates and statistical significance wras determined by the Student s t-test.
* indicates p < 0.05 and ** indicates p < 0.01.
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Fig. 5. G9a recruitm ent to the CYP7A1 promoter and subsequent H3K9 methylation 
after bile acid treatment is dependent on SHP expression. (A.B)* HepG2 cells were 
transiently transfected with either pSUPER or pSUPER siSHP and treated with 50 (JM 
CDCA for 18 hr. (A). Levels of mRNA were determined by real-time RTPCR relative to 
36B4 mRNA levels. The S.E.M. was calculated from triplicate samples and statistical 
significance was determined by the Student’s t-test. ** indicates p < 0.01. (B) ChLP assays 
were performed using antibodies against SHP and G9a. Precipitated chromatin was 
extensively washed and analyzed as described in the legend to Fig. 4E. (C). HepG2 cells 
were infected with Ad-empty or Ad-siSHP and treated with 50 (JM CDCA or vehicle for 18 
hr. Cells were then collected for ChIP assays using antibodies against SHP? G9a; 
diacetylated H3K9/K14, or dimethylated H3K9, or using normal serum (NS). Precipitated 
chromatin was extensively washed and analyzed as described in the legend to Fig. 4E.
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Fig. 6. Expression of the G9a-DN mutant inhibits H3K9 deacetylation as well as 
methylation and blocks recruitment of the Swi/Snf-Brm complex to the CYP7A1 
prom oter in CDCA-treated HepG2 cells. HepG2 cells were infected at a MOI of 10 
with either Ad-G9a-DN or Ad-empty and 24 hr after infection, cells were treated with 
50 pM CDCA or vehicle for 18 hr. (A). The mRNA levels of CYP7A1 were measured 
by real time PCR. (B, D) The infected cells were immunoprecipitated using antibodies 
against dimethylated H3K9, or diacetylated H3K9/K14, antibodies against Brm, 
BAF170, mSin3A, HDAC-1, HDAC-2, NcoRl, or HDAC-3 and normal serum (NS) as 
described in the legend to Fig 4E. Precipitated chromatin was extensively washed and 
isolated DNA was analyzed by semi-quantitative PCR using primer sets specific for 
human CYP7A1 as described in the legend to Fig 4E. (C, E) The intensities of bands 
in three independent experiments were determined using Image J program and 
analyzed as described in Fig 4C. (A-E). The S.E.M lor triplicate determinations is 
shown and the statistical significance was determined by the Student s t-test. 
indicates p ^  0.05, ** indicates p ^  0.01, and NS refers to statistically not significant.
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Fig. 7. Functional interplay between SHP-recruited HDACs and G9a in altering 
CYP7A1 prom oter chromatin structure. (A). TSA treatment completely reversed
enhancement of SHP inhibitor}' activity by G9a. Cos-1 cells were cotransfected with 200 ng 
Gal4-TATA-luc, 300 ng CMV-p-gal, 100 ng of GaI4-HNF-4, 50 ng of pcDNA3-PGC-l, 25 
ng of pcDNA3-SHP, and 500 ng of pCMV-G9a, and 6 hr after transfection, cells were 
treated with increasing amounts of TSA for 16 hr as indicated. Luciferase and 3- 
galactosidase were determined in cell extracts and firefly luciferase activities were 
normalized by dividing by P-galactosidase activities, (B, C). Deacetylation at H3K9 is a 
prerequisite for G9a-mediated methylation. HepG2 cells were pretreated with 100 nM of 
TSA and 1 hr later, cells were additionally treated with 25 jjM CDCA or vehicle for 7 hr. 
(B). CYP7A1 mRNA levels were measured by real time RTPCR. (C). Cells were collected 
for ChIP assays using antibodies against diacetvlated H3K9/K14, dimethylated H3K9, or 
G9a, or using normal serum (NS). (D) The intensities of bands were determined by Image J 
program and analyzed as described in Hg 4C. (B-D). The S.E.M. from triplicate 
determinations is shown and statistical significance w'as determined by the Student's t-test.
* indicates p < 0.05 and ** indicates p < 0.01. NS indicates statistically not significant.
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Fig. 8. Acute liver-specific inhibition of G9a activity by G9a-DN disrupted bile acid 
homeostasis and de-represses Cvp7al and Cyp8bl in mice fed cholic acid. About 1 x
109 active viral particles (Ad-G9a-DN or Ad-empty) were injected into a mouse tail vein, 
and 3 days after infection, mice were fed normal or 0.5% cholic acid-containing chow for 
5 hr or 24 hr. Liver, gall bladder, and small intestine were collected for further analyses. 
(A). Liver nuclear extracts were prepared from 3 mice for each group infected with Ad- 
empty or Ad-G9a-DN and immunoprecipitated with SHP antibody or control IgG. The 
immunopreciptates were used as the source of enzyme in in vitro HMT assays. GST-H3 
(1-84) (WT) or GST-H3 mutant (H3R9) was used as histone substrates, Tlie HMT 
reaction samples wfere analyzed as described in the legend to Fig. 2A. (B). Total bile acid 
pool size was measured from bile acid levels in gall bladder, liver, and the entire small 
intestine in mice fed normal or 0.5% cholic acid-supplemented chow for 5 hr or 24 hr. 
Total bile acid pool size was determined as described in Materials and Methods. The
S.E.M. from samples from 3 mice are shown. * indicates p < 0.05 and NS refers to 
statistically not significant. (C, D). Mice were infected with either Ad-G9a-DN or Ad- 
empty and 3 days later, mice were fed normal or 0.5% cholic acid-containing chow' for 5 
hr (C) or 24 hr (D). As a control, normal uninfected mice were also analyzed in parallel. 
Total RNA was isolated from liver and subjected to quantitative real time RTPCR using 
primer sets specific for Cyp7al, CypSbl, and SHP, and the amounts of PCR product was 
divided by the amount of 36B4 PCR product. The S.E.M. is shown for samples from 6 
mice for 5 hr feeding and 3 mice for 24 hr feeding groups. Differences between Ad- 
empty and Ad-G9a-DN samples were analyzed by the Student t-test. * indicates p < 0.05 
and N.S. refers to statistically not significant.
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Fig. 9. Coordinated sequential recruitment of HDACs, G9a, and Swi/Snf-Brm in the 
SHP-mediated suppression of CYP7A1 in the hepatic bile acid metabolism. Bile acid-
induced SHP may compete with coactivator HATs, including p300, CBP, and SRC-1, at 
the CYP7A1 promoter, which contributes to a decrease in histone acetylation initially as 
proposed before. SHP directly interacts with HDACs and G9a through its C-and N- 
terminus, respectively, recruiting these cofactors to the promoter, which results in 
deacetylation and subsequent dimethylation at the H3K9. H3K9 methylation and 
deacetylation create a binding surface for the recruitment of the Swi/Snf-Brm complex, 
which results in ATP-dependent chromatin remodeling and subsequent gene silencing of 
CYP7A1.
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C h a p te r  T h re e
I 300 is a u  itical metabolic regulator by coactivating the bile acid 
i eceptoi I* XR and its activity is constitutively elevated in ob/ob mice 
Abstract
The bile acid receptor FXR controls lipid and glucose homeostasis by regulating 
expression of target genes, including an orphan receptor SHP, but how FXR activity' is 
modulated remains unclear. Here, we report that the p300 acetylase coactivates FXR- 
mediated SHP induction in vivo by acetylating both FXR and histones at the SHP 
promoter but its activity is dysregulated in ob/ob mice. FXR/p300 interaction, their 
recruitment to the SHP promoter, and acetylation of FXR and histones were increased by 
FXR agonists. Down-regulation of p300 decreased acetylated FXR and histones and 
abolished SHP induction and also altered expression of other FXR target genes such that 
beneficial metabolic profiles would be expected. Strikingly, in ob/ob mice, FXR/p300 
interaction and their recruitment to the SHP promoter and acetylated FXR and histones 
were constitutively increased, leading to constitutively elevated SHP expression. 
Inhibition of p300 activity may provide promising molecular targets for treating 
metabolic diseases.
In tro d u c t io n
Famesoid X receptor (FXR) is a member of the nuclear receptor superfamily (30) and a 
biosensor for endogenous bile acids (29, 48). Upon activated by physiological 
concentration of bile acids, FXR regulates expression of numerous metabolic target genes
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in liver, kidney, and intestine (15). A number of studies utilizing synthetic FXR ligands 
and FXR-null mice have demonstrated that FXR plays a central role in maintaining 
whole body metabolic homeostasis (44, 52).
1 \R  tegulates cholesterol and bile acid levels by induction of the orphan nuclear 
receptor and metabolic repressor, small heterodimeric partner (SHP) (7, 26). Induced 
SHP then represses the expression of cholesterol 7a-hydroxylase (CYP7A1), a key 
enzyme in bile acid biosynthesis (4, 13, 42). In addition to its role in cholesterol and 
bile acid homeostasis, functions of FXR have recently been extended to glucose and fatty 
acid metabolism, liver regeneration, and inhibition of intestinal bacterial growth (11, 12,
28, 51, 56). Although such critical roles of FXR in normal and disease states have now 
been established, the molecular mechanisms of the modulation of FXR activity in vivo 
are largely unknown.
Nuclear receptors, including FXR, collaborate with a number of transcriptional 
cofactors, coactivators and corepressors, to effectively modulate transcription ot their 
target genes (21, 41). Potential FXR cofactors have been identified in mostly in vitro 
and cultured cell studies, including the histone arginine methyltransterases, CARM1 (1) 
and PRMT1 (39), a transcriptional mediator DRIP205 (36), and a versatile metabolic 
coactivator PGC-la (55). Although potential cofactors of FXR have been described, 
whether these proteins actually regulate FXR activity in vivo remains largely unexplored.
The transcription cofoctor p300 functions in diverse biological pathways, 
including differentiation, development, and proliferation (35, 53) and expression of p300 
is altered in human gastric, colorectal, and prostate carcinomas (34). P300 is a histone 
acetyltransferase (HAT) that catalyzes the acetylation ot lysine residues not only in
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nucleosomal histones, but also in nuclear receptors, cofactors, and basal transcription 
factors, resulting in enhanced gene transcription in most cases (6, 19). Despite its role 
as a general transcription coactivator, the role of p300 in vivo in metabolic regulation 
under physiological and pathological states has not been reported.
I he well known FXR target and metabolic repressor SHP is an unusual orphan 
receptor which lacks a DNA binding domain but contains a putative ligand binding 
domain (43). SHP interacts with and inhibits the activity of numerous nuclear receptors 
that are involved in regulation of diverse metabolic pathways (2, 16, 18, 22). We 
recently demonstrated that SHP inhibits transcription of target genes by coordinately 
recruiting chromatin modifying cofactors, such as mSin3A/HDACs, G9a histone lysine 
methyltransferase, and Swi/Snf-Brm remodeling complex to target gene promoters (5, 
16). Marked alterations in cholesterol and bile acid levels in SHP-null mice have 
established a role for SHP in lipid homeostasis (17, 49). Interestingly, despite its crucial 
role in metabolic regulation, elevated SHP expression has been implicated in increased 
lipid levels in liver and serum. Prolonged liver-specific overexpression ot SHP resulted 
in a depleted hepatic bile acid pool and the accumulation ot hepatic lipids in transgenic 
mice (3). Furthermore, SHP expression is highly elevated in the leptin gene-deficient 
ob/ob mice, a mouse model of tatty liver disease, obesity, and type II diabetes (10). 
How bile acid-activated FXR induces expression of SHP and the molecular basis for the
elevated SHP expression in ob/ob mice are unknown.
Here, we report for the first time that p300 is a critical in vivo metabolic regulator
but its activity is constitutively elevated in ob/ob mice. P300 coactivates bile acid- 
activated FXR in SHP induction by acetylation of both FXR and histones at the SHP
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promoter under normal physiological condition. Strikingly however, in ob/ob mice, 
despite reduced expression of FXR compared to normal mice, the p300/FXR activity is 
substantially elevated. Interaction of p300 with FXR and acetylation of both FXR and 
histones at the SHP promoter were constitutively elevated, concomitant with abnormally 
high constitutive SHP expression in ob/ob mice.
Materials and Methods
Cells
Human hepatoma HepG2 cells (ATCC HB8065) were grown in phenol red-free 
Dulbecco’s modified Eagle’s medium (DMEM)/F12 (1:1). Cos-1 cells were grown in 
DMEM media. Media were supplemented with 100 units/ml penicillin G-streptomycin 
sulfate and 10% heat inactivated fetal bovine serum.
Adenoviral experiments
An adenoviral vector expressing p300 siRNA (Ad-sip300) was kindly provided by Dr. P. 
Rotwein. Adenoviral vectors were amplified, purified, and titered as described (5, 37). 
For downregulation of p300, HepG2 cells were infected with 5-25 MOI of Ad-empty or 
Ad-sip300 and 2 days later, cells were transfected with reporter and expression plasmids 
as indicated in figure legends, and reporter assays were done. Consistent resists were 
observed in at least 2 independent triplicate assays in each experiment.
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M o u s e  in vivo e x p e r i m e n t s
Normal mice, ob/ob mice, and FXR null mice were maintained on a 12 hr light and 12 hr 
dark cycle. CA feeding was always started at 5:00 P.M. to reduce variability between 
experiments and food intake was monitored. For adenoviral experiments, mice were 
injected with about 0.5 x 109 active viral particles (Ad-empty, Ad-flag-FXR) in 200 1^ of 
PBS via the tail vein, and 4-7 days after infection, the mice were fed normal chow or 
chow supplemented with 0.5% CA for 3 to 24 hr. All the animal use and adenoviral 
protocols were approved by the Institutional Animal Care and Use and Institutional 
Biosafety Committees at University of Illinois at Urbana-Champaign and were in 
accordance with National Institutes of Health guidelines.
R ea l  t im e  R T P C R
Total RNA was isolated using Trizol reagent and cDNA was synthesized and RTPCR 
was performed with an iCycler iQ (Biorad, Inc). The amount of PCR product for each 
mRNA was normalized by dividing by the amount of 36B4 PCR product. Sequences of 
the primers are available upon request.
A c e tv la t io n  a s s a y s
For in vitro acetylation assays, histones were purified from HeLa cells and HATs from 
Sf9 insect cells infected with baculovirus encoding each ot these proteins, as described 
(46). Purified GST, GST-FXR, or core histones were incubated with each of purified 
HATs in the presence of 3H-acetyl-CoA. After incubation at 30°C for 1 hr, the proteins 
were separated by SDS-PAGE, proteins were detected coomassie blue staining, and
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radioactivity by tluoiography. In cell and in vivo acetylation studies were done as 
described (8, 31). For ligand experiments, HepG2 cells were infected with Ad-empty' or 
Ad-flag-FXR and 24 hr later, cells were treated with CDCA, GW4064, or vehicle for 2.5 
hr in the presence of TSA and Nam and CoIP acetylation assays were done. Flag-FXR 
was expressed in cells or mouse liver by infection with Ad-flag-FXR, and flag-FXR was 
immunoprecipitated with M2 antibody and acetylated flag-FXR was detected by western 
blotting using acetyl lysine antibody (Cell signaling, Inc) or vice versa. The same 
membrane was stripped and subjected to western blotting using M2 antibody (Sigma, 
Inc).
C o I P  a s s a y s
CoIP assays were performed as described (5, 16, 37). Briefly, 1 mg of mouse liver 
nuclear extracts or 2.5 to 5 mg of liver extracts were incubated in lysis buffer (50 mM 
Tris-HCl, pH 8.0, 5 mM EDTA, 10% glycerol, 150 mM NaCl, 0.5% NP40, protease 
inhibitors, and 1 mM DTT) with 1 ^g ot antibodies and washed with lysis buffer 
(supplemented with NaCl up to 250 mM and 1% NP40) and proteins in the 
immunoprecipitates were detected by western blotting.
C h I P  a s s a y s
ChIP assays were carried out essentially as described (5, 16, 33, 37). ChIP experiments 
in HepG2, normal mice, and ob/ob mice were repeated at least 3 times with reproducible
results.
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Results
Cholic acid (CA) feeding induces the interaction of FXR with p300 in mouse liver.
In initial biochemical studies, a protein of about 300 kd was detected in a protein 
complex associated with flag-I-XR in human hepatoma HepG2 cells after treatment with 
(j\\ 4064, a synthetic FXR agonist (not shown). Therefore, to test if the transcriptional 
coactivator and histone acetyltransferase (HAT) p300 is involved in the regulation of 
FXR activity in vivo, we examined the interaction of p300 with FXR in mouse liver by 
Co IP assays. Mice were infected with Ad-flag-FXR or control Ad-empty and were fed 
normal chow or 0.5% CA-supplemented chow. Similar expression of flag-FXR was 
observed in the two groups (Supplemental Fig. SI). P300 was immunoprecipitated from 
liver nuclear extracts and flag-FXR in the immunoprecipitates was detected by western 
blotting. The levels of flag-FXR were similar in input samples, but substantially 
increased in the anti-p300 immunoprecipitates after CA feeding (Fig. 1 A).
We confirmed these results with endogenous FXR without overexpressing flag- 
FXR in mouse liver. The amount of p300 in the anti-FXR immunoprecipitates was 
increased by CA feeding (Fig. IB), while similar levels ot endogenous p300 and FXR 
were detected in the input samples (Supplemental Fig. S2). These CoIP studies indicate 
that CA feeding increases the interaction of p300 with FXR in mouse liver, suggesting 
that p300 may be involved in bile acid-activated FXR signaling in vivo.
F X R  t r a n s a c t i v a t i o n  is e n h a n c e d  b y  p300  in a l i g a n d -d e p e n d e n t  m a n n e r .
To test if the p300/FXR interaction is functionally relevant, the effect of p300 on FXR 
transactivation was initially examined using cell-based reporter assays. Exogenous
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expression of p300 enhanced FXR transactivation in a primary bile acid, 
chenodeoxycholic acid (CDCA)-dependent manner (Fig. 1C, lanes 4-6). In contrast to 
p300 wild type, a p3()() HA I mutant did not enhance FXR transactivation but instead 
reduced the activity, presumably by acting as a dominant negative mutant (Fig. 1C, lanes,
4, 7, 8). These results suggest that HAT activity is required for p300-mediated 
coactivation of FXR.
Since the above experiments utilized overexpression of p300, we also tested the 
effects of down-regulation of endogenous p300 on FXR activity. Infection with Ad- 
sip300 decreased the p300 mRNA levels in HepG2 cells by 80% (Supplemental Fig. S3). 
Expression of FXR and RXR activated the FXRE reporter in the presence of GW4064 or 
CDCA, and infection with increasing amounts of Ad-sip300, but not of Ad-empty, 
progressively inhibited FXR transactivation (Fig. ID). These results indicate that p300, 
at normal endogenous levels, functions as a coactivator of agonist-activated FXR. Since 
SHP is a direct FXR target, we also tested if p300 was a FXR coactivator for 
transactivation of the SHP promoter. Treatment with FXR agonists substantially 
increased FXR transactivation of the SHP promoter (Fig. IE). Ad-sip300 markedly 
reduced the FXR activity in a dose-dependent manner, whereas Ad-empty had little 
effect. These results indicate that p300 functions as a coactivator for FXR 
transactivation of the SHP promoter.
C A  fe e d in g  in d u c e s  r e c r u i t m e n t  o f  p300 to th e  S H P  p r o m o t e r  in  m o u se  l iver
We next examined whether CA feeding increased the association ot endogenous p300 
with the native Shp promoter in mouse liver using chromatin immunoprecipitation (ChIP)
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assays. To fust ensure that CA feeding effectively altered expression of Shp and 
Cyp7al, a key enzyme in bile acid biosynthesis that is suppressed by Shp, mRNA levels 
of these genes were monitored. The Shp mRNA levels w-ere increased by 3 hr, whereas 
Cyp7a 1 mRNA levels were substantially and progressively decreased with time, after CA 
feeding (Fig. 2A). In ChIP assays, association of FXR and p300 was markedly 
increased after CA feeding (Fig. 2B). Consistent with p300 recruitment, acetylation of 
histone H3 at K9/K14 was increased and these effects were not observed for the control 
GAFDH sequence (Fig. 2B). In time courses, association of FXR was detected in livers 
of untreated mice and increased at 6 hr of CA feeding (Fig. 2C). P300 was recruited to 
the Shp promoter at 3 hr of CA feeding and reached a maximum at 6 hr. Consistent 
with p300 recruitment, acetylated histone H3 levels progressively increased from 3 to 24 
hr after CA feeding (Fig. 2C).
To test if the p300 recruitment was dependent on FXR, ChIP assays were done in 
FXR-null mice. Association of FXR w'as not observed, as expected, and the association 
of p300, acetylated histones, and RNA polymerase II was also largely eliminated in these 
mice (Fig. 2D). In contrast, association of RXR was observed in wild type and FXR- 
null mice independent of CA feeding, suggesting that another nuclear receptor that could 
form a heterodimer with RXR was present at the promoter. These results suggest that 
p300 is recruited to the SHP promoter after CA feeding in a FXR-dependent manner.
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A c tiv a te d  F X R  s ig n a l in g  in c re a se s  assoc ia tion  o f  p300 an d  ac e ty la ted  h is to n es  a t  the  
S H F  p r o m o t e r .
To delineate the mechanism of p300-mediated coactivation of FXR signaling in more 
detail, the effects of FXR agonists on the association of p300 and acetylated histones with 
the Sill promoter were studied in HepG2 cells. Acetylated histone H3 was detected in 
untreated cells and the levels were increased after CDCA treatment, most dramatically by 
GW4064 treatment, which is consistent with SHP induction (Fig. 2E). Interestingly, co­
treatment with the FXR antagonist, gugglesterone (47), blocked the CDCA-mediated 
increase in histone H3 acetylation and reduced acetylation to lower than basal levels (Fig. 
2E). These results suggest that ligand-regulated FXR signaling pathways are functional 
in HepG2 cells.
In HepG2 cells, FXR association with the SHP promoter and p300 recruitment 
were markedly increased after GW4064 or CDCA treatment (Fig. 2F, G). Consistent 
with the p300 recruitment, acetylation of histone H3 was also increased. An increase in 
the association of FXR and p300 was detected as early as 1 hr after CDCA treatment
reaching a maximum at 3 to 6 hr (Fig. 2H).
To determine if p300 and FXR are simultaneously associated with the promoter, 
chromatin immunprecipitated with FXR antisera was reprecipitated with pj>00 antisera. 
SHP promoter sequences were detected in CDCA-treated samples reprecipitated b> p^ OO 
antibody (Fig. 21), suggesting that both p300 and FXR are associated with the same SHP 
promoter. These results show that p300 is recruited to the SHP promoter in a FXR 
ligand-dependent manner and provide further evidence that p300 is a FXR coactivator of
SHP induction.
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D o w n - r e g u la t io n  o f  p 3 0 0  d e c re a se s  F X R  b in d in g  an d  h is tone acety la tion  a t  th e  S H P  
p r o m o te r .
Io test it increased acetylation at the SHP promoter by FXR agonists is dependent on 
p300, endogenous p300 in HepG2 cells was down-regulated over 70% by infection with 
Ad-sip300. GW4064 treatment increased SHP mRNA levels about 3 fold and this 
increase was largely inhibited by p300siRNA (Fig. 3A). Acetylated histone H3 levels 
and association of FXR and RNA polymerase II with the promoter were increased by 
GW4064, and these increases were eliminated in cells infected with Ad-sip300 (Fig. 3B). 
Similar effects of p300 siRNA were observed with HepG2 cells treated with CDCA (Fig. 
3C, D). These results demonstrate that increased histone H3 acetylation and FXR 
binding are dependent on p300, suggesting that p300 coactivates FXR-mediated SHP 
induction by increasing acetylation of promoter histones and FXR binding to the 
promoter.
F X R  is a c e t y l a t e d  b y  p3 0 0  in vitro a n d  in cells.
Binding of transcriptional activators to promoter chromatin is increased not onlv b> 
acetylation of histones but also by acetylation of the activators (27, 45). Since FXR 
binding to the SHP promoter was inhibited by down-regulation of p300 (Fig. 3), we 
further considered whether FXR can be acetylated by p300. To test this possibility, we 
first examined if p300 can d.rectly interact with FXR and then if P300 can acetylate FXR. 
P300 was associated with GST-FXR in vitro, but in contrast to in vivo results (Fig. 1), the 
interaction was independent of treatment with CDCA (not shown) orGW4064 (Fig. 4A).
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lo test if FXR can be acetylated by p300, purified GST-FXR, GST, or core 
histones were incubated with HATs. Auto-acetylation of p300, CBP, pCAF was 
detected (1 lg. 4B, asterisks). GST-FXR was acetylated by p300 and to a lesser extent 
by CBP, but not detectably by pCAF or GCN5. In contrast, histones were robustly 
acetylated by all these acetylases (Fig. 4C) and control GST was not acetylated 
(Supplemental Fig. S4). These studies indicate that FXR is acetylated by p300 in vitro.
To test if FXR is acetylated in cells, we first examined whether inhibition of 
deacetylation of proteins by the deacetylase inhibitors, trichostatin A (TSA) and 
nicotinamide (Nam), increased acetylated FXR levels. HEK293 cells were transfected 
with expression plasmids for flag-FXR and then treated with TSA and7or Nam. 
Acetylation of flag-FXR was detected by CoIP, immunoprecipitation with acetyl lysine 
antibody followed by detection of flag-FXR in the immunoprecipitates by western 
blotting as described (31). The levels of acetylated FXR were increased by either of the 
deacetylase inhibitors, indicating that FXR is normally acetylated in cells. Similar 
results were observed in HepG2 and Cos-1 cells (not shown).
Next, to determine if p300 acetylates FXR, cells were cotranslected with 
expression plasmids for flag-FXR and P300 wt or a p300 HAT mutant, and acetylated 
FXR levels were detected. Acetylation of flag-FXR was detected in cells expressing 
flag-FXR only and exogenous expression of p300 markedly increased the acetylation 
(Fig. 4D). In contrast, with the p300 HAT mutant, acetylated FXR levels were lower 
than basal levels. These results indicate that FXR can be acetylated by p300 m cells.
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A c e ty la te d  F X R  lev e ls  a r e  in c re a se d  a f te r  F X R  ag o n is t t re a tm e n t
Since vve observed that both the interaction of FXR with p300 and the association of FXR 
and p300 with the Shp promoter in mouse liver was increased after CA feeding (Fig. 1, 
2), we postulated that FXR acetylation would be increased in cells by treatment with a 
FXR agonist. To test this possibility, the effects of CDCA or GW4064 on acetylated 
FXR levels were examined in HepG2 cells. Acetylated FXR levels were increased in 
cells treated with CDCA or GW4064 in the presence of HADC inhibitors (Fig. 4E, upper 
panel), whereas the amounts of flag-FXR were similar between groups (Fig. 4E, lower 
panel). These results indicate that acetylated FXR levels are increased after FXR 
agonist treatment.
E ffec ts  o f  d o w n - r e g u la t io n  o f  p300  on the  exp ression  o f  F X R  ta rg e t
To further explore a general metabolic function of p300, we tested the effects of p300 
siRNA on expression of FXR target genes in HepG2 cells. Injection of Ad-sip300 or 
the Ad-p300 HAT mutant was lethal in mice for unknown reasons so we could not 
conduct these experiments in vivo. In HepG2 cells, p300 mRNA levels were reduced 
by 70% by Ad-sip300 infection and were not altered by CDCA or GW 4064 treatment 
(Fig. 5A). The functions of representative FXR target genes that are examined in this 
study are briefly summarized in Fig. 5E. CDCA or GW4064 treatment reduced 
CYP7A1 mRNA levels about 70% as expected and while infection with Ad-sip300 
reduced basal levels of CYP7A1. a further reduction was not observed with agonist 
treatment (Fig. 5B). Down-regulation of P300 resulted in substantial decreases in SHP 
mRNA levels and significant decreases in BSEP mRNA levels in cells treated with
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vehicle or FXR agonists (Fig. 5B). In contrast, while the mRNA levels of ApoCII or 
ApoE were not changed by Ad-sip300 infection, PLTP and VLDLR mRNA levels were 
surprisingly increased (Fig. 5C). The mRNA levels of ApoAl were reduced by CDCA 
treatment and down-regulation of p300 reversed the inhibition of ApoAI expression (Fig. 
5C). Interestingly, down-regulation of p300 substantially reduced mRNA levels of G-6- 
Pase and markedly reduced those of PEPCK (Fig. 5D).
These data indicate that down-regulation of p300 has differential effects on the 
expression of different FXR target genes. Interestingly, the changes in expression of 
genes involved in lipid metabolism are in directions that would lead to improved lipid 
profiles and those in glucose metabolism would lead to decreased serum glucose levels.
C o n s ti tu t iv e lv  e le v a te d  p 3 0 0  ac tiv ity  in ob/ob m ice
Prolonged expression of SHP in transgenic mice was associated with detrimental lipid 
profiles and development of fatty livers (3). Consistent with these results, SHP 
expression was abnormally elevated in ob/ob mice and knock-down of the SHP gene 
resulted in beneficial metabolic effects in these mice (10). Since p300/FXR activity is 
critical for SHP gene expression, we hypothesized that SHP expression might be 
abnormally elevated, at least in part, by detects in the p300/FXR pathway in ob/ob mice.
To test this possibility, we first compared mRNA levels of lipogenic factors, 
FXR, p300, and SHP in normal and ob/ob mice. The mRNA levels ot lipogenic factors, 
SREBP-lc and PPARy were increased about 2-3 fold and their lipogenic target genes, 
such as FAS and SCD1, were dramatically increased in the ob/ob mice (Fig. 6A). While 
the mRNA levels of p300 were not significantly changed, FXR mRNA le\els \ere
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surprisingly reduced by 80% in ob/ob mice (Fig. 6B). SHP mRNA levels were elevated 
about 5 fold in the ob/ob mice, which is consistent with a recent report (10) The 
mRNA levels of BSEP, another well known FXR target and hepatic bile acid transporter, 
were modestly reduced in ob/ob mice but the decrease was not statistically significant.
In Coll assays, the interaction of FXR with p3Q0 w-as markedly and 
constitutively elevated in ob/ob mice compared to normal mice (Fig. 6C). Consistent 
with the increased interaction of FXR with p300 in ob/ob mice, acetylated FXR levels 
were dramatically elevated in these mice compared to normal mice (Fig. 6D). 
Acetylated FXR levels were not detected in control IgG-precipitated samples 
(Supplemental Fig. S5). Notably, the mobility of FXR was slightly reduced in samples 
from ob/ob mice, which may reflect increased post-translational modification of FXR in 
these mice. These results suggest that FXR is highly acetylated in ob/ob mice, which 
may be associated with increased SHP expression in these mice. These data provide a 
potential link between FXR hyperacetylation and metabolic dysfunction in these mice.
To further explore the molecular basis of dysregulation of the p300/FXR activity 
in ob/ob mice, we compared protein occupancy in normal and ob/ob mice at the SHP 
promoter and at the BSEP promoter, another FXR target gene, which responds similarly 
to CA feeding or CDCA treatment in normal mice and in HepG2 cells (Fig. 5B) (S. Fang 
and J. K. Kemper, unpublished data). In ChIP assays, association of FXR (in spite of its 
decreased expression, Fig. 6B), p300, and RNA polymerase II with the SHP promoter 
was increased in ob/ob mice compared to normal mice (Fig. 6 E, G). Acetylation at 
histone H3K9/K14, which is associated with gene activation (14), was markedly 
increased in ob/ob mice at the SHP promoter. Conversely, methylation of histone
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113K9, which is associated with gene suppression (5, 20), was decreased at the SHP 
promoter in ob/ob mouse liver. Interestingly, these changes at the SHP promoter were 
not detected at the BSEP promoter in ob/ob mice (Fig. 6 F, H). These results suggest 
that gene activation by h\R/p300 pathway is a gene-selective process in these mice. 
The mechanism underlying this gene selectivity is not clear from the present data. The 
changes in ob/ob mice are complex and regulation of SHP and BSEP genes is likely to be 
a combinatorial process involving multiple transcription factors and defects in upstream 
signaling pathways. Nevertheless, these data suggest that constitutively elevated p300 
activity and highly elevated acetylation levels of FXR and histones at the SHP promoter 
may cause, at least in part, constitutive and abnormal elevation of SHP expression in 
these mice.
Discussion
From animal in vivo studies using normal mice, FXR null mice, and ob/ob mice, along 
with molecular mechanistic studies in HepG2 cells, we have obtained compelling 
evidence that p300 is a critical in vivo metabolic regulator in bile acid signaling. 
Coactivation of bile acid-activated FXR by p300 is critical tor induction of the SHP gene, 
a well known FXR target and metabolic repressor, in normal mice. Surprisingly 
however, the p300 activity is constitutively elevated in ob/ob mice, a mouse model of 
fatty liver disease and diabetes, such that acetylation levels of both FXR and histones at
the SHP promoter are constitutively and highly elevated.
Several lines of evidence indicate that P300 coactivates FXR induction via 
acetylation of both target gene histones and FXR. The most convincing evidence for
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acetylation of histones by p300 is that p300 was recruited to the SHP promoter and 
histone acetylation was increased after CA feeding or treatment with FXR agonists but 
the increased histone acetylation was nearly completely blocked by down-regulation of 
p300 (Fig. 2). f urther, the time-course of increased acetylation at the promoter after 
bile acid treatment correlated with that of p300 in both HepG2 cells and mouse liver in 
vivo. Finally, a mutation of p300 which eliminates HAT activity also eliminated 
coactivation by p300 of FXR transactivation of the SHP promoter. These results 
demonstrate that p300 enhances SHP induction, at least in part, by acetylation of 
chromatin histones.
Coactivator HATs, such as p300, can also directly acetylate nuclear receptors 
and modulate their activity. Acetylation of transcription factors, such as, ER, foxo-
l,and AR, has been shown to alter their DMA binding ability, cofactor interaction, or 
protein stability (6, 19, 32). It was recently demonstrated that the activity of a 
transcriptional coactivator, PGC-la, was substantially altered by its acetylation state 
which was dependent on GCN5 acetylase and SIRT1 deacetylase (23, 40). In the 
present studies, bile acid treatment increased interaction of FXR with p300 and the 
rec ru itm en t of FXR/p300 to the SHP promoter in mouse liver and in HepG2 cells. 
C o n sis te n t with these observations, acetylated FXR levels were increased by FXR 
ag on ists  (Fig. 4E). Furthermore, acetylated FXR levels were increased by exogenous 
expression of p300, but were decreased by expression of a p300 HAT mutant. These 
studies strongly suggest that acetylation of FXR, in addition to histone acetylation,
contributes to coactivation of FXR by p30G.
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We observed unexpected, intriguing results that down-regulation of p300 altered 
the expression of metabolic FXR target genes such that beneficial metabolic profiles 
would be expected (1 ig. 5). The expected effects of the down-regulation are complex 
since direct targets of FXR/p300, like SHP, would be expected to be down-regulated and 
indirect targets ot FXR via SHP induction would be expected to be up-regulated. 
Furthermore, if these metabolic genes are also regulated by other transcription factors 
that are coactivated by p300, decreased expression w?ould be expected. Nevertheless, 
for the genes involved in lipoprotein metabolism, down-regulation of p300 resulted in a 
dramatic increase in the expression of the VLDL receptor gene which should increase the 
metabolism of triglyceride-rich lipoproteins and, therefore, decrease the levels of 
triglycerides, which is a beneficial result. Down-regulation of p300 also increased the 
basal levels of ApoCII, ApoE, and PLTP. While modest, these changes should result in 
increased synthesis of an HDL component, transfer of phospholipid to HDL, and 
increased metabolism of chylomicrons and VLDL. Each of these changes would result 
in improved lipid profiles that may reduce the probability of cardiovascular disease. For 
enzymes related to glucose metabolism, p300 reduced expression of G6Pase and PEPCK, 
both of which are involved in the production of glucose and would contribute to 
decreased serum glucose levels, a beneficial effect in diabetic states.
To examine the potential role of p300 in pathological states, we examined the 
regulation of the SHP gene by FXR/p300 activity in ob/ob mice. Abnormally elevated 
SHP expression has been observed in ob/ob mice and KKAj mice, mouse models for 
fatty liver and diabetes, suggesting that elevation of SHP expression may be associated 
with these metabolic diseases (10). Consistent with these studies, liver-specific
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prolonged overexpression of SHP was shown to result in depleted hepatic bile acid pools 
and accumulation of hepatic lipids by indirectly promoting hepatic lipogenesis in 
transgenic mice (3). Also, SHP was a negative regulator of energy homeostasis, and 
decreased lipid levels and increased insulin sensitivity were detected SHP-null mice (50). 
Abnormal elevation of SHP expression, therefore, has been implicated as a key factor in 
disorders of lipid and glucose metabolism.
In ob/ob mice, while p300 mRNA levels were not significantly increased, 
surprisingly, FXR mRNA levels were dramatically reduced compared to normal animals. 
Remarkably, despite decreased FXR expression, interaction of FXR with p300 was 
substantially increased and FXR/p300 recruitment to the SHP promoter w'as also 
constitutively and highly increased in ob/ob mice compared to normal mice (Fig. 6). 
Consistent writh these results, levels of acetylated FXR and histones at the SHP promoter 
were substantially elevated, concomitant with elevated SHP expression in ob/ob mice. 
These results suggest that the protein complex at the SHP promoter and modification of 
histones are similar in ob/ob mice fed normal chow- and normal mice after CA feeding, 
except that the activation is exaggerated in ob/ob mice, with constitutively elevated FXR 
acetylation (Fig. 7). Our data, together w?ith previous studies (3, 10), suggest that 
elevated p300 activity and subsequent elevated SHP expression may cause, at least in
part, the pathogenesis observed in the ob/ob mice.
Interestingly, expression of a second FXR target and hepatic bile acid 
transporter, BSEP gene, was not elevated in the obob mice. This result suggests that 
the activation of the FXR/p300 pathway is gene-selective in these mice. The 
mechanisms underlying this gene selectivity is not clear from the present data but
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presumably is related to complex, combinatorial regulation of these genes. Additional 
research will be required to better understand the mechanism of the selective regulation 
of FXR target genes by p300.
P300 is a transcriptional coactivator critically involved in cell differentiation, 
development, and cell proliferation, and dysregulation of p300 activity has been detected 
in various human carcinomas (34). Our studies and previous studies suggest that 
expression and activity of critical coregulators, such as p300 and PGC-la, must be tightly 
regulated to maintain normal metabolic homeostasis and that dysregulation of these 
cofactors leads to metabolic disease. For instance, the key metabolic regulator PGC-la 
is critically involved in metabolic adaptation to fasting by stimulating entire program of 
hepatic gluconeogenesis and fatty acid (3-oxidation (24, 38). These responses are 
lacking in PGC-la null mice resulting in hypoglycemia and increased lipid levels in the 
liver (25). However, interestingly, constitutively elevated PGC-la activity has been 
implicated in pathological states as well, resulting in elevated hepatic glucose production 
and subsequently elevated fasting glucose levels (9, 54). Analogous to these PGC-la 
studies, our results demonstrate that p300 is a critical in vivo metabolic regulator in bile 
acid signaling but its activity is dysregulated and constitutively elevated in ob/ob mice. 
Reducing hepatic SHP expression by inhibiting the p300 activity, therefore, may have 
beneficial effects on metabolic diseases and inhibiting the p300 activity may be an 
attractive molecular target for treating metabolic disorders.
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harvested for q-RTPCR (A, C) or ChIP assays (B, D). The SEM was determined or
statistical significances as by Student’s t test, * p v 0.05 (n :>)•
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F ig . 4. F X R  is acety  la te d  by  p300. (A). T w o Mg o f p u rif ied  co n tro l G S T  o r  G S T - 
F X R  w a s  in c u b a te d  w ith  35S-p300 and further subjected to GST pull down assay. 
(B) The HATs were purified and incubated with 2 pg of purified GST-FXR, GST, or 
core histones (CH), and with 3H-acetyl CoA. The proteins were separated by 
electrophoresis and radioactivity was detected by fluorography. (C) HEK293 cells 
were transfected with expression plasmids for flag-FXR and cells were treated with 
the deacetylase inhibitors, TSA (1 pM) and/or Nam (10 mM) in the presence of 25 pM 
CDCA for 6 hr. (D) HEK293 cells were cotransfected with expression plasmids as 
indicated, and treated with TSA and Nam in the presence of 1 pM GW4064 for 6 hr. 
(E) HepG2 cells were infected with Ad-empty or Ad-tlag-FXR and 24 hr later, cells 
were treated with CDCA, GW4064 or vehicle in the presence of TSA and Nam tor 2.5 
hr and cells extracts were prepared. (C-E) Acetylated proteins were 
immunoprecipitated from cell extracts with acetyl lysine antibod) an  ^ in t e 
immunoprecipitates and total FXR were detected with M~ antibodv.
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F ig . 5. E ffc c ts  o f  p 3 0 0  d o w n -re g u la tio n  oil expression  o f m e tab o lic  F X R  ta rg e t  genes
(A-D) HepG2 cells were infected with Ad-sip300 or Ad-empty and 3 days later, cells 
were treated with ligands overnight and the mRNA levels of FXR target genes were 
determined by qRT-PCR. V, C, and GW indicate vehicle, 50 UMCDCA, and 100 nM 
GW4064, respectively. Statistical significance was determined by the Student t test, p 
< 0.05, NS indicates not statistically significant (n=3). (E) FXR target genes examined m 
this study are listed with a brief description of the function ot the gene product.
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Fig. 6 , c o n t  D y s re g u la t io n  o f  p300 /F X R  activ ity  in ob/ob m ice. (A, B) Normal or 
ob/ob mice were fed standard chow and livers w^ ere collected and mRNA levels of 
genes in liver extracts were determined by qRT-PCR and normalized to 36B4 mRNA 
levels. The SEM was calculated from results from three sets of animals. (C, D) 
Normal or ob/ob mice were injected with Ad-flag-FXR and fed standard chow' and 
liver extracts were prepared. (C) P300 was immunoprecipitated from liver extracts 
and the presence of flag-FXR in the immunoprecipitates wras detected by western 
blotting using M2 antibody. Precipitation with IgG served as a negative control. (D) 
In vivo acetylation CoIP assays. Liver extracts were incubated with M2 antibody or 
acetyl lysine antibody and the presence of acetylated FXR in the immunoprecipitates 
was detected by western blotting using acetyl lysine antibody or M2 antibodies, 
respectively. The membrane was stripped and reprobed with M2 antibody to detect 
flag-FXR levels in the immunoprecipitates (lower panel). Consistent results were 
observed in 4 CoIP assays from two sets of animals. (E. H) ChIP assays in mouse 
livers from normal and ob/ob mice were carried out. Representative results are 
shown in E and F and the mean and standard error from 4 independent assays is 
shown in G and H. Statistical significance was determined by the Student’s t test. 
**p< 0.01 * p < 0.05, NS indicates statistically not significant.
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Normal mouse
dynam ic 
FXR acetylation
d im e th y la te d  H3K9
[ M e )  (Me)
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Fig. 7. Regulation of FXR activity by p300 in normal and ob/ob mice In normal 
mice, p300 is critical in FXR-mediated SHP expression in bile acid signaling. 
Unliganded FXR/RXR heterodimers are associated with the promoter and histones H3 
are dimethylated at H3K9 (repressive histone mark), resulting in low basal levels of SHP 
expression. Activation of FXR signaling by CA feeding or FXR agonists increases the 
FXR interaction with p300 and recruits p300 to the SHP promoter, resulting in transient 
increases in both FXR acetvlation and histone H3 acetylation at K9,14 (activated histone 
mark) with concomitant demethylation at K9. FXR binding to the promoter is also 
increased. These changes result in transient induction of the SHP gene in response to 
bile acids. In contrast, in ob/ob mice, the p300/FXR pathway is dysregulated. Despite 
surprisingly low expression of FXR, the interaction of p300 with FXR and recruitment of 
p300/FXR to the SHP promoter are highly elevated. Protein complex at the SHP 
promoter and modification of histones in ob/ob mice fed normal cho\\ resem e t ose o 
normal mice after CA feeding, except that the e x p r e s s i o n  of SHP is consti ivey 
elevated in the ob/ob mice with constitutive acetylation ot an is ones a le 
promoter. These effects are specific to the SHP gene because they were not detected at 
the BSEP promoter, another well known direct FXR target.
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Immunoblotting: mouse liver
Fig. SI. Mice were injected with Ad-flag-FXR or control Ad-empty in 200 ml PBS 
and 5 days later, mice were fed normal standard chow or 0.5% CA-supplemented 
chow for 6 hr, and liver nuclear extracts were prepared. Flag-FXR levels and control 
RXR levels were detected by western blotting.
_______ In p u t
C.A.(6hr) -____-  +
P300-> -
Fig. S2. Mice were fed normal or CA chow for 6 hr and liver nuclear extracts were 
prepared. Levels of endogenous p300 and FXR were detected by western blotting.
H e p G 2  c e lls :  q R T -P C R
Ad-Virus 
CDCA
Empty Empty sip300 
+ +u u u n  -  «
Fig. S3. HepG2 cells in 24 well plates were infeeted with 5-25 MOI of Ad-stp300 or 
Ad-empty and 2 days later, the cells were treked with 50 " ^ D C A  ° r 
ovemighi. Then, levels of p300 mRNA were determined by qRl-PCR and mRNA
levels were normalized to those of 36B4 (n-3).
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In vitro a c e ty la t io n
GST GST-FXR
Acetyiase: p300 p300
250KDa -J
<-Ac:GST-FXR
25KDa
Fig. S4. Two mg of purified GST or GST-FXR was incubated with purified p300 in the 
presence of 'H-acetyl Co A. The proteins were separated by electrophoresis and 
radioactivity was detected by fluorography. Acetylated GST-FXR (about 85kd) is 
indicated by an arrow. Auto-acetylated p300 is indicated by an asterisk.
Ad-fiag:FXR
IP: M2 IP: IgG
Normal ob/ob Normal ob/ob
WB:.
Ac-lys
WB:
M2'
» i *
X  strip ^strip
m m 1 L ______
Fig. S5. In vivo acetylation ColP assays. Liver extracts from normal or ob/ob mice were 
incubated with M2 antibody or control mouse IgG and the presence of acetylated FXR in 
the immunoprecipitates was detected by western blotting using acetyl lysine antibody. 
The membrane was stripped and reprobed with M2 antibody to detect flag-FXR levels in 
the immunoprecipitates (lower panel).
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Preliminary additional studies
LSD-1 is a potential cofactor in SHP-mediated CYP7A1 inhibition
Post-translational modifications of histones control gene expression by altering chromatin 
structure or by serving as platforms to recruit other cofactors. Among histone 
modifications, methylation was thought to be an irreversible modification until a 
demethylase was recently identified for the first time. In 2004, it was found that lysine 
specific demethylase (LSD-1) is a bona fide histone lysine demethylase (12).
LSD-1, a nuclear amine oxidase homolog, contains the C-terminal amine oxidase 
domain and a central SWIRM (SWDp, Rsc8p and Moira) domain. SWIRM domains 
have been found in many chromatin-associated proteins and might serve as DNA binding 
motifs (1, 4). The oxidation reaction by LSD-1 reverses methylated lysines to 
unmodified lysines in a FAD-dependent manner. LSD-1 specifically demethylates 
mono- and di-methylated H3K4 whereas demethylation of tri-methylated H3K4 is 
prevented in the absence of protonated nitrogen which is required for oxidation reaction 
(12). In general, methylation of H3K4 is likely related to gene activation, and in 
contrast, its demethylation accompanies gene repression. Thus, the role of LSD 1 to 
remove the gene activation mark on H3K4 contributes to suppression of gene 
transcription. Recently, it was reported that LSD-1 is present in a ligand-activated 
androgen receptor complex and is able to demethylate mono- and dimethylated iI3K9 to 
induce gene expression (9), suggesting that LSD-1 may serve as both a coactivator and a
corepressor to regulate gene expression.
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Previously, I reported that SHP represses CYP7A1 gene transcription by 
interacting with histone methyltransferase G9a which methylates H3K9 at the promoter 
of CYP7A1. Since histone modifications do not occur independently but affect each 
other to modulate gene transcription, I have further examined whether LSD-1 is involved 
in SHP-mediated CYP7A1 repression through demethylation of H3K4 in bile acid 
signaling.
First, I examined if LSD-1 directly interacts with SHP in vitro. GST fusions 
with SHP or fragments of SHP (Fig. I A) that had been bound to glutathione-Sepharose 
were incubated with 'S-labeled LSD-1. LSD-1 bound to SHP or SHP mutants 
containing the N-terminal domain (1-92 amino acids), whereas no binding was detected 
with SHP mutants lacking this region (Fig.lA). Consistent with this result, 35S-labeled 
SHP bound to GST fusioned LSD-1 protein (Fig.IB), suggesting that LSD-1 directly 
interacts w'ith SHP in vitro. To test if LSD-1 associates with SHP in mouse hepatocytes 
in vivo, the interaction between SHP and LSD-1 in mouse hepatocytes was examined by 
co-immunoprecipitation. SHP was detected in the anti-LSD-1 immunoprecipitates and 
conversely, LSD-1 was detected in the anti-SHP immunopreciptiates (data not shown). 
These results indicate that SHP directly interacts with LSD-1 in hepatic cells.
To examine whether exogenously expressed LSD-1 increases the inhibitory 
activity of SHP, transient reporter assays were performed. Transfection of increasing 
amounts LSD-1 expression plasmid with a constant amount ot SHP plasmid increased 
inhibition of the HNF-4/ PGC-la activation in a dose-dependent manner (Fig.2A). To 
test if LSD-1 inhibition of HNF-4/PGC-la activation is dependent on SHP, LSD-1 was 
expressed in transfected Cos-1 cells with or without expression of SHP. In the absence
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ot SHP, LSD-1 had little effect on the inhibition of HNF-4/PGC-la transartivation 
(Fig.2B), suggesting that SHP is required for the inhibitory effect of LSD-1. To 
evaluate the role of LSD-1 in the inhibitory activity of SHP, exogenous plasmids 
expressing siRNA against LSD-1 were co-transfected with reporter genes. Transient 
knock-down of LSD-1 completely reversed the combinatorial inhibitory activity of SHP 
and LSD-1 using Gal4 reporter system in Cos-1 cells (Fig.2C) and CYP7A1 promoter- 
luciferase system in HepG2 cells (Fig.2D). Transient knock-down of endogenous LSD-
I by siRNA completely reversed the bile acid-mediated repression of the CYP7A1 gene 
expression (Fig.2E,F), suggesting that LSD-1 is involved in SHP-mediated suppression 
ofCYP7Al expression.
If the interaction of LSD-1 with SHP is physiologically relevant for bile acid 
metabolism, then LSD-1 should be recruited to the transcriptionally suppressed 
promoters of CYP7A1, the well-known SHP target gene, in mice fed cholic acid. To 
examine whether endogenous LSD-1 is recruited to the O  P 7A1 promoter in response to 
cholic acid, ChIP assays were performed in normal-ted or cholic acid-fed mouse. My 
ChIP assay data showed that recruitment oi SHP and LSD-1 and the levels of di­
methylated H3K9 were increased whereas the levels of acetylated H3K9/K14 and di­
methylated H3K4, the specific substrate of LSD-1, and recruitment of RNA polymerase
II were decreased at the promoter of CYP7A1 gene with bile acid treatment in \i\o
(Fig-3).
Thus, my preliminary data suggest that LSD-1 is a potential corepressor which 
enhances the inhibitory activity of SHP by demethylation of H3K4 to suppress CYP7A1 
transcription in response to bile acid signaling.
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S IR T l  a n ta g o n iz e s  th e  p 3 0 0  m ed ia ted -F X R  tran sac tiv a tio n  by d eace ty la tio n  o f F X R
SIRTl, also known as silent mating type information regulation 2 homolog, is an enzyme 
that deacetylates proteins to regulate cellular processes, such as gene silencing, 
metabolism and aging (5). Recently, it has been revealed that SIRTl removes acetyl 
groups from modified lysines in both histones and regulatory proteins, such as PGC-la, 
LXR, and pS3 in a NAD+-dependent manner (2, 8, 10, 11, 14). SIRTl deacetylase and 
GCN5 acetylase have been shown to modulate the activity of a coactivator PGC-la in the 
regulation of hepatic glucose. While GCN5 decreased PGC-la activity by altering the 
intra-nuclear distribution of PGC-la, SIRTl increased its activity by deacetylating PGC- 
la  (7, 11). In addition to its role in deacetylation of transcriptional factors, SERTl has 
been shown to deacetylate histones in chromatin of target genes (6, 13). SIRTl was 
shown to be recruited to the promoters of SIRTl target genes such as PPARy, a key factor 
for adipogenesis, and suppressed the expression of this gene by further recruiting the 
corepressors, NcoRl and SMRT (10). SIRTl was also recruited to the promoter of 
UCP2 gene and inhibited transcription, resulting in increased ATP production and insulin
secretion in pancreatic p cells (3).
My recent findings showed that p300 acetylates FXR, as well as histones, to 
initiate gene transcription. Interestingly, the FXR acetylation was markedly increased 
by treatment with nicotine amide (NAM), a specific SIRTl inhibitor, indicating that 
SIRT1 may be involved in the modulation of FXR activity by FXR deacetylation. Thus, 
I have examined if SIRTl has a potential role in the regulation of FXR acti y
To test if SIRTl is associated with FXR, 1 examined the interaction of SIRTl 
with FXR by coinnnunoprecipitation assay. Mice were infected with Ad-flag FXR or
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control Ad-empty and were fed normal chow or 0.5% CA-supplemented chow. Flag- 
FXR v\as immunoprecipitated from liver nuclear extracts by M2 and endogenous SIRTl 
in the immunoprecipitates was detected by western blotting. The levels of flag-FXR 
were similar in input samples (data not shown). The interaction of SIRTl with FXR 
substantially decreased in the M2 immunoprecipitates after CA feeding (Fig.4A). A 
similar result was observed in an endogenous experimental setting without expression of 
flag-FXR. The amount of SIRT1 in the anti-FXR immunoprecipitates was decreased by 
CA feeding (Fig. 4B), while similar levels of endogenous SIRTl were detected in the 
input samples. These CoIP studies indicate that CA feeding decreases the interaction of 
SIRTl with FXR in mouse liver, suggesting that SIRTl may be involved in unliganded- 
FXR signaling in vivo.
Recent studies have shown that SIRTl deacetylates a number of transcriptional 
factors. Thus, I tested whether SIRTl can deacetylate FXR that was acetylated by p300 
in vitro. GST or GST-FXR proteins were acetylated by p300 in vitro. After in vitro 
acetylation assay, samples were subjected to deacetylation assay with SIRTl in tlie 
presence or absence of NAD+, the SIRTl cofactor. SIRTl deacetylated FXR that had 
been acetylated by p300 in a NAD+-dependent manner (Fig.5A). To test the functional 
role of SIRTl in FXR transactivation, transient reporter assays were performed. My 
preliminary data showed that SIRTl antagonizes p300-mediated FXR transactivation 
(Fig.5B). Consistent with reporter assays, my ChIP data showed that SIRTl is
associated at the native promoter of SHP gene and is dissociated from the promoter of
• < * /r;' cr\ ciioppstmc that SIRTl functions as aSHP gene by bile acid treatment (Fig.5C), sugg
corepressor to suppresses FXR target gene transcription.
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Recently, 1 found that the association of p300 with FXR is markedly increased in 
obese mice compared to normal mice. Interestingly, my preliminary 
coimmunoprecipitation data showed that the association of SIRTl with FXR is markedly 
decreased in obese mice compared to normal mice (Fig.6A). In addition, SIRTl is not 
associated with the SHP native promoter without bile acid feeding in obese mice (Fig.6B), 
suggesting that the control of FXR transactivation by SIRTl is dysregulated in disease 
states, resulting in constitutively elevated SHP gene expression in obese mice.
Thus, my preliminary' data suggest that SIRTl also plays a key role as a 
deacetylase to control FXR activity and modulate transcription of the FXR target genes in 
response to bile acid signaling.
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Input GST FL 1 3 1+2 2+3
■35S-LSD-1
B
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I n p u t  GST GST-LSD-1
35S-SHP
Fig. 1. LSD-1 associates with SHP in vitro. (A) Schematic diagrams of SHP and fall
length (FL) GST-SHP, and GST-SHP deletion mutants. RID and RD
interacting and intrinsic repression domains, respec l'®5- ' 0
in vitro, and GST pull down assays were performed The input represents, 10/oofthe
35S-labeled LSD-1 used in the binding reactions. The position o
(B). A schematic diagram of the GST-LSD-1.
down assays were performed. The input represents 10% of the -S-labeled SHP 
in the reactions.
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Fig. 2, cont. LSI)-1 enhances SHP inhibition of CYP7A1 transcription. (A-B). 
Cos-1 cells were cotransfected with 200 ng of 5Gal4-TATA-luc, 300 ng of CMV-B- 
gal, 50 ng of Gal4-HNF-4 (G4HNF-4), 100 ng of pcDNA3-PGC-la, 10 ng of 
pcDNA3-SHP and increasing amounts of pcDNA3-LSD-l as indicated. (C). Cos-1 
cells were cotransfected with 200 ng of 5Gal4-TATA-luc, 300 ng of CMV-B-gal, 50 
ng of Gal4-HNF-4 , 50 ng of pcDNA3-PGC-la, 10 ng of pcDNA3-SHP, and 
amounts of pcDNA3-LSD-1 or pSUPER-LSD-1 which expresses LSD-1 siRNA. (D). 
HepG2 cells were transfected with 200 ng o f -1887 hCYP7Al-luc, 300 ng of CMV- 
B-gal, 300 ng of pcDNA3-LSDl and 100 ng of pSUPER-LSD-1. Eighteen hour after 
transfection, cells were treated with 10 pM of CDCA for 6 hr. (E-F). HepG2 cells 
were transfected with 3 pg of pSUPER-empty or pSUPER-siLSD-1. Forty-eight 
hour after transfection, cells were treated with vehicle or 50 pM of CDCA overnight. 
Cells were subjected to QRT-PCR to measure the endogenous mRNA levels of LSD- 
1 and CYP7A1.
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ChIP assay: Mouse liver
mCyp7a1
-330' +29
mCyp7a1 
C.A.: -  +
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K9/K14
d iM e t
H3K4
d iM e t
H3K9
SHP
LSD-1
RNA 
Pol II
Fig. 3. LSD-1 is recruited to the endogenous CYP7A1 promoter and H3K4 is 
demethylated in mice fed cholic acid. Mice were fed normal or 0.5% cholic acid 
(C.A.)-supplemented chow for 24 hr and livers were collected for ChIP assays. At the 
top, a schematic diagram of the mouse Cyp7al promoter with the positions of the 
primers used for the PCR reactions is shown. Soluble chromatin was isolated and pre­
cleared as described in Materials and Methods and immunoprecipitated with antibodies 
against SHP, LSD-1, diacetylated H3 K9/K14 (di-AcH3 K9/K14), or dimethylated 
H3K9 (di-Met H3K9), dimethylated H3K4 (di-Met H3K4), RNA polymerase II or 
normal serum (NS). Precipitated chromatin was extensively washed. Genomic DNA 
was isolated from the input chromatin before precipitation (total) or from the 
precipitated chromatin and was analyzed by semi-quantitative PCR using primer sets 
specific for Cyp7al.
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A CoIP: mouse liver
ip
Input mlgG M2
Ad-virus Empty f:FXR Empty f:FXR Empty f:FXR 
CA " * ' * " + "  +  - +  _ +  
SIRT1
B CoIP: mouse liver
ip
Input
C.A.
SIRT1
jlflG FXR Ab
-  + -  + -  +
Fig. 4. Effects of CA feeding on interaction of FXR with SIRTl in mouse liver
(A) Mice infected with Ad-flag-FXR or control Ad-empty were fed normal or 0.5% 
CA-supplemented chow for 6 hr and livers were collected for CoIP. 
Immunoprecipitates from liver extracts were incubated with control IgG or M2 
antibody and SIRTl in the immunoprecipitates was detected by wrestem blotting. (B) 
Uninfected mice were fed as described in (A). Liver extracts were subjected to CoIP 
and immunoprecipitates with FXR antibody or IgG were isolated and the presence ol 
SIRTl in the immunoprecipitates was detected by western blotting.
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Mouse liver ChIP
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Fig. 5. SIR Tl antagonizes FXR transactivation. (A). Two mg ot GST-FXR 
acetylated by p300 was incubated with 1 mg ol GST or GST-SIRTl in the presence or 
absence of 200 mM NAD+ and analyzed by fluorography. (B). HEK293 cells were 
cotransfected with 200 ng of (FXRE^tk-luc, 5 ng ot CM\ -FXR, and increasing 
amounts (25, 50, 100 ng) of expression plasmids for wild type (WT) or catalyticall\ 
inactive (MT) p300 or SIRTl. (C) Mice were fed normal or 0.5 % CA chow tor 6 hr 
and ChIP assays were done using the indicated antisera.
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Hg. 6. Differential association of SIRT1 with FXR in normal and ob/ob mouse 
liver (A). Normal or ob/ob mice were infected with Ad-flag-FXR or Ad-empty and 5 
days later, liver extracts were immunoprecipitated and the presence of flag-FXR in the 
anti-p300 immunoprecipitates and the presence of SIRT1 in the M2 
immunoprecipitates were determined by western blotting. (B). ChIP assays were done 
in livers from normal and ob/ob mice fed nomial chowr using the indicated antibodies.
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Conclusion
The main purpose of this study is to address the functional roles of the orphan nuclear 
receptors, SHP and FXR, and their cofactors in bile acid signaling that regulates 
expression of genes involved in a number of metabolic pathways. My major findings to 
support the roles of SHP and FXR in bile acid signaling are as follows: 1) p300 and 
SIRT1 are critical in vivo FXR cofactors for modulation of FXR transactivatior. by 
acetylation or deacetylation of both histones and FXR. 2) In the absence of bile acid, 
unliganded FXR/RXR heterodimers recruit a corepressor complex including SIRT1 to the 
SHP promoter. SIRT1 is associated with FXR to inhibit FXR transactivation by 
deacetylation. Histones H3 are dimethylated at K9, a repressive marker, resulting in a 
low basal level of SHP expression. 3) In the presence of bile acids, SIRT1 is dissociated 
from FXR whereas p300 interaction with FXR increases resulting in a transient increase 
of acetylation levels of both FXR and histones which correlates with initiation of 
transcription of SHP gene. 4) In obese mice, FXR and histones are constitutive!)- and 
highly acetylated and p300/FXR activity is elevated in the absence ot bile acid. 5) Bile 
acid-induced SHP directly interacts with and recruits G9a and LSD 1 to the 
CYP7A1 promoter and promotes to mediation of H3K9 and demthylation of H3K4, 
respectively, which correlates with suppression of transcription ot the CY g
Interestingly, SHP sequentially recruits its cofactors, including HDAC, Brm based
~ j r First SHP recruits HDAC to
Swi/Snf chromatin remodeling complex and G9 .
deacetylate core histones, and then recruits G9a to methylates H3K9. Fi ),
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recruits Bmi-based Swi/Snf chromatin remodeling complex and changes the chromatin 
structure which is associated with gene repression (Fig.l). These findings delineate the 
molecular mechanisms of bile acid signaling which regulate cholesterol/bile acid 
homeostasis in the liver.
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Figure 1. Roles of orphan nuclear receptors, SHP and FXR, and their cofactors in bile acid signaling
My preliminary data showed that SHP mRNA levels reached almost maximum
•evels (a little over 2-fold) as early as 3 hr after bile acid treatment and were not further
increased at longer times, implying the existence ot an autoregulation for SHP expression
normal metabolic physiology. The 
unknown, but several
which prevents prolonged increases in expression in 
mechanism o f autoregulation for SHP expression 
previous studies implied that SHP itself may regulate us own expression vi
regulatory loop. It has been shown that SHP
strongly interacts with LRH-1 in both
mammalian two-hybrid assay and in vitro pulldown assay
and efficiently suppresses the
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transactivation of LRU-1 (2). Notably, a LRH-1 -responsive element was also identified 
at the SHP promoter (6), thus, SHP is likely to bind to LRH1 at its promoter and 
negatively regulate its own gene expression.
Why the expression of SHP is autoreagulated has not been determined. One 
highly likely possibility of many is that the autoregulation of SHP expression may be a 
critical regulatory process to protect the body from the malignant effects caused by 
abnormally overexpressed SHP. Recently, it was reported that abnormal elevated SHP 
expression is associated with metabolic diseases. Study of SHP-transgenic mice showed 
that prolonged overexpression of SHP resulted in a depletion of hepatic bile acid pool and 
the accumulation of hepatic lipids (1). Consistent with these studies, deletion of the 
SHP gene in leptin-deficient obese mice resulted in a beneficial metabolic effect with 
reduced lipid levels in the liver (4), implying that prolonged elevated SHP expression 
leads to abnormal metabolic diseases. In spite of the key role of SHP in diverse 
hepatic metabolic regulations, the mechanisms of regulation of SHP expression remain 
largely unknown.
Recent study showed that the SHP expression is abnormally elevated in obese 
mice compared to normal mice (4). My recent work revealed that SHP expres 
abnormally elevated in obese mice, at least in part, as a result of dysregulated p3 
activity. P300 was constitutively associated with the SHP promoter and with
acetylation of histones as well as FXR, which correlates with abnormal elevated SHP
c i d t i  infraction with FXR was marked 
expression in obese mice. In contrast, SIRT1
, , SIRT1 was able to deacetylate FXR
decreased in obese mice compared to normal mite.
in vitro, thus, dissociation of SIRT1 from FXR in obese mice may result m con
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FXR acetylation, which abnormally enhances SHP gene expression in obese mice. 
These results provide a correlation between dysregulated functions of transcriptional 
factors to modulate FXR activity and abnormal elevated SHP expression in metabolic 
disorders.
In my preliminary data, SIRT1 was shown to deacetylate FXR in vitro and 
decrease p300-mediated FXR transactivation, thus, increasing SIRT1 activity would be a 
novel therapeutic method to restore the dysregulated FXR acetylation in hepatic 
metabolic diseases. Previous study reported that treatment with resveratrol, a 
polyphenol found in red wine, stimulated SIRT1 activity, resulting in increasing DNA 
stability and expanding lifespan in yeast (3). Recently, it was found that resveratrol also 
impacts mitochondrial function and metabolic homeostasis. Treatment of mice with 
resveratrol increased consumption of oxygen in muscle fiber and protected mice against 
diet-induced obesity and insulin resistance by stimulating the activity of SIRT1 (5). 
Interestingly, I found that resveratrol treatment decreased the levels of FXR acetylation in 
obese mice (data not shown). This finding suggested that resveratrol is likely to 
modulate FXR activity by stimulating SIRT1 activity to deacetylate FXR, which may 
result in decreasing FXR activity to reduce SHP gene expression in obese mice.
SHP and FXR function as pleiotropic regulators ot diverse biological functions 
by regulating numerous genes in multiple pathways. Their transcriptio 
regulated by interactions with cofactors, are tightly controlled to maintain me 
homeostasis in normal physiology. If their functional activities are dysresgulated, it 
may cause metabolic diseases. My recent findings showed that the functiona 
between p300 and S1RT1 is critical to modulate FXR activity and main
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levels of SHP expression in the body. Thus, restoring the functional balance between 
p300 and S1RT1 to modulate FXR activity normally may be an attractive strategy to 
reduce abnormal elevated SHP expression which is associated with some hepatic 
metabolic disorders. However, the mechanisms underlying functional balance between 
transcriptional factors, including p300 and SIRT1, are largely unknown. Therefore, my 
studies to define the function and mechanism of the p300 and SIRT1 in the regulation of 
FXR activity and SHP expression may facilitate the design of novel therapeutic methods 
for treating metabolic diseases, such as, fatty liver, hypercholesterolemia, diabetes, and 
obesity.
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